



華潤醫療控股有限公司

China Resources Medical Holdings Company Limited

(Incorporated in the Cayman Islands with limited liability)
(於開曼群島註冊成立之有限責任公司)

Stock Code 股票代號 : 1515

2022

INTERIM REPORT

中期報告





CONTENTS

目錄

- 2** Corporate Information
公司資料
- 5** Management Discussion and Analysis
管理層討論與分析
- 19** Corporate Governance Highlights
企業管治摘要
- 21** Other Information
其他資料
- 28** Independent Review Report
獨立審閱報告
- 30** Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income
中期簡明綜合損益及其他全面收益報表
- 31** Interim Condensed Consolidated Statement of Financial Position
中期簡明綜合財務狀況報表
- 33** Interim Condensed Consolidated Statement of Changes in Equity
中期簡明綜合權益變動報表
- 35** Interim Condensed Consolidated Statement of Cash Flows
中期簡明綜合現金流量報表
- 37** Notes to Interim Condensed Consolidated Financial Information
中期簡明綜合財務資料附註
- 75** Definitions
釋義



Corporate Information

公司資料

Directors

Executive Directors

Mr. SONG Qing (*Chairman of the Board*)
Mr. CHENG Libing (*Chief Executive Officer*)
Ms. REN Yuan (*Chief Financial Officer*)
Mr. SHAN Baojie

Non-executive Director

Mr. HU Hui

Independent Non-executive Directors

Mr. WU Ting Yuk, Anthony
Mr. KWONG Kwok Kong
Ms. CHIU Kam Hing Kathy
Mr. LEE Kar Chung Felix

Audit Committee

Mr. KWONG Kwok Kong (*Chairman of Committee*)
Ms. CHIU Kam Hing Kathy
Mr. HU Hui

Remuneration Committee

Ms. CHIU Kam Hing Kathy (*Chairman of Committee*)
Mr. LEE Kar Chung Felix
Ms. REN Yuan

Nomination Committee

Mr. SONG Qing (*Chairman of Committee*)
Mr. LEE Kar Chung Felix
Mr. KWONG Kwok Kong

Authorised Representatives

Mr. CHENG Libing
Mr. SO Yiu Fung

Company Secretary

Mr. SO Yiu Fung

董事

執行董事

宋清先生(董事長)
成立兵先生(總裁)
任遠女士(首席財務官)
單寶杰先生

非執行董事

胡輝先生

獨立非執行董事

胡定旭先生
鄺國光先生
趙金卿女士
李家聰先生

審核委員會

鄺國光先生(委員會主席)
趙金卿女士
胡輝先生

薪酬委員會

趙金卿女士(委員會主席)
李家聰先生
任遠女士

提名委員會

宋清先生(委員會主席)
李家聰先生
鄺國光先生

授權代表

成立兵先生
蘇堯鋒先生

公司秘書

蘇堯鋒先生

Headquarters and Principal Place of Business in Mainland China

14/F, Kunlun Center Office Building
No. 9, Fuyi Street
Fengtai District, Beijing
China

Principal Place of Business in Hong Kong

Room 2603, 26/F, China Resources Building
26 Harbour Road,
Wanchai, Hong Kong SAR

Registered Office

Harneys Services (Cayman) Limited
4th Floor, Harbour Place
103 South Church Street
PO Box 10240, Grand Cayman
KY1-1002, Cayman Islands

Principal Share Registrar and Transfer Office in Cayman Islands

Harneys Services (Cayman) Limited
4th Floor, Harbour Place
103 South Church Street
PO Box 10240, Grand Cayman
KY1-1002, Cayman Islands

Hong Kong Branch Share Registrar

Computershare Hong Kong Investor Services Limited
Shops 1712-1716, 17th Floor
Hopewell Centre
183 Queen's Road East
Wanchai
Hong Kong SAR

Auditor

Ernst & Young
Certified Public Accountants
Registered Public Interest Entity Auditor
27/F, One Taikoo Place
979 King's Road
Quarry Bay
Hong Kong SAR

總部及中國內地主要營業地點

中華人民共和國
北京市豐台區
福宜街9號院
崑崙中心寫字樓14樓

香港主要營業地點

中華人民共和國
香港特別行政區
灣仔
港灣道26號
華潤大廈26樓2603室

註冊地址

Harneys Services (Cayman) Limited
4th Floor, Harbour Place
103 South Church Street
PO Box 10240, Grand Cayman
KY1-1002, Cayman Islands

開曼群島主要股份過戶登記處

Harneys Services (Cayman) Limited
4th Floor, Harbour Place
103 South Church Street
PO Box 10240, Grand Cayman
KY1-1002, Cayman Islands

香港證券登記分處

香港中央證券登記有限公司
中華人民共和國
香港特別行政區
灣仔
皇后大道東183號
合和中心
17樓1712-1716室

核數師

安永會計師事務所
執業會計師
註冊公眾利益實體核數師
中華人民共和國
香港特別行政區
鰂魚涌
英皇道979號
太古坊第一座27樓

Corporate Information

公司資料

Legal Adviser

As to Hong Kong law

Jingtian & Gongcheng LLP
Suites 3203-3207, 32/F
Edinburgh Tower
The Landmark
15 Queen's Road Central
Hong Kong SAR

Principal Bankers

China Merchants Bank
2nd Floor, Tower A
156 Fuxingmennei Street
Xicheng District
Beijing, China

Industrial and Commercial Bank of China
Room 102, Block 6, Court 2, East Baizhifang Street
Xicheng District
Beijing, China

DBS Bank Ltd, Hong Kong Branch
18th Floor, The Center
99 Queen's Road Central
Central
Hong Kong SAR

China Construction Bank (Asia) Corporation Limited
25/F, CCB Tower
3 Connaught Road Central
Central
Hong Kong SAR

Stock Code

1515

Company Website

www.crmedical.hk

法律顧問

香港法律

競天公誠律師事務所有限法律責任合夥
中華人民共和國
香港特別行政區
皇后大道中15號
置地廣場
公爵大廈
32樓3203-3207室

主要往來銀行

中國招商銀行
中華人民共和國
北京市
西城區
復興門內大街156號
A座2樓

中國工商銀行
中華人民共和國
北京市
西城區
白紙坊東街2號院6號樓102室

星展銀行有限公司香港分行
中華人民共和國
香港特別行政區
中環
皇后大道中99號
中環中心18樓

中國建設銀行(亞洲)股份有限公司
中華人民共和國
香港特別行政區
中環
干諾道中3號
中國建設銀行大廈25樓

股份代號

1515

公司網站

www.crmedical.hk

Management Discussion and Analysis

管理層討論與分析

BUSINESS REVIEW

The consolidated revenue of the Group for the Reporting Period amounted to RMB2,850 million (Corresponding Period: RMB1,772 million), and net profit for the Reporting Period amounted to RMB215 million (Corresponding Period: RMB205 million). Earnings per share of the Company amounted to RMB0.16 (Corresponding Period: RMB0.16). The results of the Company recorded a stable growth and it was mainly attributable to the effective prevention and control of the COVID-19 epidemic in China, and also most of the member hospitals recorded a better year-on-year growth in their business volume, revenue and operating results during the Reporting Period that the overall number of out-patients and in-patients respectively increased by 66.1% and 11.4%, and medical business revenue of our member hospitals recorded a year-on-year increase of 6.4%.

Since the corresponding documents in relation to the daily operation arrangement of China Resources Wugang (Hubei) Hospital Management Co. Ltd. (the “**Joint Venture**”) have been executed between it and the Company, the Group has obtained the practical capability to direct the relevant activities of the Joint Venture unilaterally and gained control over the Joint Venture, and its financial statements have been retrospectively consolidated into the Group’s financial statements since January 30, 2022. In addition, since the corresponding documents in relation to the daily operation arrangement of the Wugang Hospital Group have been executed between it and the Joint Venture, together with the effect of the previous constitution amendments on the above hospitals, the Group has obtained the practical capability to direct the relevant activities of such hospitals unilaterally and gained control over them, and therefore the financial statements of the Wugang Hospital Group have been retrospectively consolidated into the Group’s financial statements since January 30, 2022.

業務回顧

本集團報告期共實現綜合營業額人民幣28.5億元(相應期間：人民幣17.72億元)，淨利潤為人民幣2.15億元(相應期間：人民幣2.05億元)及每股盈利人民幣0.16元(相應期間：人民幣0.16元)。本公司業績錄得穩定增長主要是由於我國新冠病毒疫情得到有效防控，以及報告期本公司下屬成員醫院在業務量、收入和經營利潤方面均較去年同期錄得提升，整體門診人次及住院人次分別增長了66.1%和11.4%，成員醫院之醫療業務收入則錄得同比增長6.4%。

按本公司與華潤武鋼(湖北)醫院管理有限公司(「合營公司」)簽立的與合營公司日常營運安排有關的相應文件，本集團具備獨立指導合營公司的相關活動的實際能力，並獲得了合營公司的控制權，因此其財務報表追溯自2022年1月30日起合併至本集團的財務報表。此外，按合營公司與武鋼醫院集團就武鋼醫院集團日常營運安排簽訂的相關文件，加上此前章程修訂對上述醫院產生的影響，本集團已具備獨立指導上述醫院的相關活動的實際能力，並獲得了相關醫院的控制權，因此武鋼醫院集團的財務報表亦追溯自2022年1月30日起合併至本集團的財務報表。

Management Discussion and Analysis

管理層討論與分析

Scale of our operation

As of June 30, 2022, the Group managed and operated a total of 120 medical institutions in 8 provinces and cities in the PRC. During the Reporting Period, the number of outpatient visits and in-patient visits of our in-network hospitals were approximately 7,870,000 and 143,000, respectively and representing the respective year-on-year increase of 66.1% and 11.4%.

List of Medical Institutions under the Group's Management and Operation

Province/City	省份/城市	Grade III Hospitals 三級醫院	Grade II Hospitals 二級醫院	Grade I Hospitals and Community Centres 一級醫院及社區中心	Clinics & Other Medical Institutions 診所及其他醫療機構	Total 合計
Beijing	北京	2	4	11	29	46
Shandong	山東	—	2	2	10	14
Shanxi	山西	—	1	—	—	1
Jiangsu	江蘇	—	2	—	—	2
Anhui	安徽	1	1	19	8	29
Hubei	湖北	2	—	3	16	21
Guangdong	廣東	1	1	—	2	4
Guangxi	廣西	—	2	1	—	3
Total	合計	6	13	36	65	120

經營規模

截至2022年6月30日，本集團在中國8個省、市共管理運營120家醫療機構。於報告期內，本集團成員醫院門診量和住院量分別約為787萬人次和14.3萬人次，分別較去年同期增長66.1%及11.4%。

本集團管理營運醫療機構分佈表

Operating data for Year 2022H1

2022年上半年營運數據

Type	類型	Number of beds in operation 運營床位數	Utilization rate of beds 床位使用率	Number of patients 診療人次		Revenue from medical business (RMB'000) 醫療業務收入(人民幣千元)			Total 合計
				Number of out-patients 門診人次	Number of in-patients 住院人次	Revenue from out-patient visits 門診收入	Revenue from in-patient visits 住院收入	Revenue from physical examination 體檢收入	
Self-owned Hospitals ^(Note)	自有醫院 ^(註)	9,864	73.7%	4,941,511	126,100	1,523,301	1,729,963	34,185	3,287,449
IOT/OT Hospitals	IOT/OT醫院	1,505	51.6%	2,928,457	16,777	473,450	241,399	14,917	729,766
Subtotal	小計	11,369	70.7%	7,869,968	142,877	1,996,751	1,971,362	49,102	4,017,215

Operating data for Corresponding Period

相應期間營運數據

Type	類型	Number of beds in operation 運營床位數	Utilization rate of beds 床位使用率	Number of patients 診療人次		Revenue from medical business (RMB'000) 醫療業務收入(人民幣千元)			Total 合計
				Number of out-patients 門診人次	Number of in-patients 住院人次	Revenue from out-patient visits 門診收入	Revenue from in-patient visits 住院收入	Revenue from physical examination 體檢收入	
Self-owned Hospitals ^(Note)	自有醫院 ^(註)	9,293	75.0%	3,315,393	108,626	1,345,877	1,667,830	39,882	3,053,589
IOT/OT Hospitals	IOT/OT醫院	1,804	53.7%	1,423,253	19,644	438,646	260,471	24,442	723,559
Subtotal	小計	11,097	71.6%	4,738,646	128,270	1,784,523	1,928,301	64,324	3,777,148

Note: In respect of the operating data statistics, the abovementioned self-owned hospitals refer to all consolidated hospitals and unconsolidated hospitals of the Group, and except for the IOT/OT hospitals managed by the Group.

註：就營運數據統計目的，上述自有醫院即指本集團之所有併表醫院及非併表醫院，不包括由本集團管理的IOT/OT醫院。

Management Discussion and Analysis

管理層討論與分析

Financial data

Financial data for Year 2022H1

財務數據

2022年上半年財務數據

2022H1	2022年上半年	Total	Segment results			Administrative expenses	Other gains and expenses
			Self-owned Hospitals	IOT/OT Hospitals	Other derived businesses		
RMB'000	人民幣千元	合計	自有醫院	IOT/OT醫院	其他衍生業務	行政費用	其他收益及費用
Revenue from goods and services	商品及服務收益	2,850,489	2,619,040	224,136	7,313	—	—
Cost of sales and services	銷售及服務成本	(2,326,223)	(2,162,106)	(153,492)	(10,625)	—	—
Other income	其他收入	35,975	28,316	3,778	3,881	—	—
Other gains and losses	其他收益及虧損	351	351	—	—	—	—
Selling and distribution expenses	銷售及分銷費用	(8,684)	(6,331)	(2,193)	(160)	—	—
Administrative expenses	行政費用	(256,204)	(237,078)	(13,386)	(5,740)	—	—
Finance costs	財務費用	(1,180)	(1,172)	—	(8)	—	—
Impairment losses on financial assets, net	金融資產減值虧損淨額	(2,939)	(2,555)	—	(384)	—	—
Other expenses	其他費用	(5,042)	(5,025)	—	(17)	—	—
Share of profit of a joint venture/associates	應佔合營/聯營公司利潤	31,209	31,209	—	—	—	—
Segment results	分部業績	317,752	264,649	58,843	(5,740)	N/A 不適用	N/A 不適用
Headquarters operating expenses	總部運營費用	(36,364)	—	—	—	(36,364)	—
Other profit or loss	其他損益	(16,423)	—	—	—	—	(16,423)
Finance costs	財務費用	(10,790)	—	—	—	—	(10,790)
Income tax	所得稅	(39,428)	—	—	—	—	(39,428)
Net profit or loss	淨損益	214,747	264,649	58,843	(5,740)	(36,364)	(66,641)
Revenue from medical business (Notes)	醫療業務收入(註)	4,017,215	3,287,449	729,766	—		

Notes:

During the Reporting Period:

- (1) Self-owned hospitals include: Jian Gong Hospital, Jinan Zhong Qi Hospital, Huaikuang Hospital Group, the Run Neng Hospitals, Guangdong 999 Brain Hospital, Xukuang Hospital and Huaibei City Mental Health Center, the Wugang Hospital Group and also Huai'yin Hospital. This segment also includes the return on the Group's investments to Jing Mei Hospital.
- (2) IOT hospitals include: Mentougou Hospital, Mentougou Traditional Chinese Medicine Hospital, Mentougou Hospital for Women and Children, Shunyi District Konggang Hospital, the Second Hospital of Shunyi District.
- (3) OT hospitals include: Yantai Zhifu Hospital, Yuenianhua Rehabilitation Hospital.

註：

於報告期內：

- (1) 自有醫院包括：健宮醫院、濟南重汽醫院、淮礦醫院集團、潤能系醫院、廣東三九腦科醫院、徐礦醫院及淮北市精神(心理)衛生中心、武鋼醫院集團以及淮陰醫院。相關分部也包括因本集團投資京煤醫院所獲得的收益。
- (2) IOT醫院包括：門頭溝區醫院、門頭溝區中醫院、門頭溝區婦幼保健院、順義區空港醫院、順義區第二醫院。
- (3) OT醫院包括：煙台芝罘醫院、悅年華康復醫院。

Management Discussion and Analysis

管理層討論與分析

Financial data for Corresponding Period

相應期間財務資料

Corresponding Period	相應期間	Total	Segment results				Administrative expenses	Other gains and expenses
			Self-owned Hospitals	IOT/OT Hospitals	Other derived businesses	分部業績		
RMB'000	人民幣千元	合計	自有醫院	IOT/OT醫院	其他衍生業務	行政費用	其他收益及費用	
Revenue from goods and services	商品及服務收益	1,772,123	1,567,174	192,259	12,690			
Cost of sales and services	銷售及服務成本	(1,377,549)	(1,230,513)	(133,842)	(13,194)			
Other income	其他收入	20,530	9,632	4,615	6,283			
Selling and distribution expenses	銷售及分銷費用	(7,952)	(6,051)	(1,901)	—			
Administrative expenses	行政費用	(127,506)	(112,883)	(11,760)	(2,863)			
Finance costs	財務費用	(1,177)	(1,144)	—	(33)			
Reversal of impairment losses on financial assets, net	金融資產減值虧損轉回淨額	1,012	1,012	—	—			
Other expenses	其他費用	(1,139)	(1,008)	—	(131)			
Share of profit of a joint venture/associates	應佔合營/聯營公司利潤	43,134	43,134	—	—			
Segment results	分部業績	321,476	269,353	49,371	2,752	N/A 不適用	N/A 不適用	
Headquarters operating expenses	總部運營費用	(61,379)				(61,379)		
Other profit or loss	其他損益	14,166					14,166	
Finance costs	財務費用	(4,701)					(4,701)	
Share of profit of associates	應佔聯營公司利潤	580					580	
Income tax	所得稅	(64,817)					(64,817)	
Net profit or loss	淨損益	205,325	269,353	49,371	2,752	(61,379)	(54,772)	
Revenue from medical business (Notes)	醫療業務收入(註)	3,777,148	3,053,589	723,559	—	N/A 不適用	N/A 不適用	

Notes:

For Corresponding Period:

- Self-owned hospitals include: Jian Gong Hospital, Jinan Zhong Qi Hospital, Huaikuang Hospital Group, the Run Neng Hospitals, Guangdong 999 Brain Hospital, Xukuang Hospital and Huaibei City Mental Health Center, and also Huai'yin Hospital (since June 30, 2021). This segment also includes the return on the Group's investments to Jing Mei Hospital and the Wugang Hospital Group.
- IOT hospitals include: Mentougou Hospital, Mentougou Traditional Chinese Medicine Hospital, Mentougou Hospital for Women and Children, Shunyi District Konggang Hospital, the Second Hospital of Shunyi District.
- OT hospitals include: Yantai Zhifu Hospital, Yuenianhua Rehabilitation Hospital and Tai'an City Hospital.

註:

於相應期間:

- 自有醫院包括: 健宮醫院、濟南重汽醫院、淮礦醫院集團、潤能系醫院、廣東三九腦科醫院、徐礦醫院及淮北市精神(心理)衛生中心, 以及淮陰醫院(自2021年6月30日起)。相關分部也包括因本集團投資京煤醫院和武鋼醫院集團所獲得的收益。
- IOT醫院包括: 門頭溝區醫院、門頭溝區中醫院、門頭溝區婦幼保健院、順義區空港醫院、順義區第二醫院。
- OT醫院包括: 煙台芝罘醫院、悅年華康復醫院及泰安市立醫院。

Management Discussion and Analysis

管理層討論與分析

SEGMENT RESULTS

In the first half of 2022, the aggregated results of all segments amounted to about RMB318 million, which decreased slightly by approximately 1.2% as compared with the Corresponding Period. During the Reporting Period, a number of our member hospitals achieved satisfactory improvement in terms of their operating results, but since the Huaiyin Hospital was still in the integration stage and together with the impacts of pandemics, its revenue from medical business and profit contribution recorded year-on-year drop. The segment profits during the Reporting Period dropped slightly due to these factors.

Segment Results – Self-owned Hospitals

During the Reporting Period, although Huaiyin Hospital is still in the integration stage, and we were also under the impact of the epidemic in China, the Group's self-owned hospitals recorded satisfactory business growth as a whole. The medical business revenue of the self-owned hospitals segment increased by 7.7% year-on-year to approximately RMB3.29 billion and the segment results recorded a decrease of 1.7% to approximately RMB265 million.

分部業績

2022年上半年各業務分部業績合計約為人民幣3.18億元，較相應期間輕微下降約1.2%。報告期內本集團大部分成員醫院實現了較理想的內涵增長，但因淮陰醫院仍處於併購整合期，疊加疫情反覆等因素，其2022年上半年的醫療業務收入和利潤貢獻同比顯著下降，綜合上述情況導致報告期內分部業績同比輕微下降。

分部業績 – 自有醫院

報告期內，儘管淮陰醫院尚處於併購整合期，且國內疫情多地散發，本集團內其他自有醫院業績增長仍較為理想。自有醫院分部的醫療業務收入同比增長7.7%至約人民幣32.9億元，分部業績錄得同比下降1.7%至約人民幣2.65億元。

		Corresponding		Year-on-Year Change	
		2022H1 2022年 上半年	Period 相應期間	RMB '000 人民幣千元	Percentage 百分比
Self-owned Hospitals	自有醫院	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	Percentage 百分比
Revenue from medical business	醫療業務收入	3,287,449	3,053,589	233,860	7.7%
General healthcare services	綜合醫療服務	121,373	82,813	38,560	46.6%
Hospital management services fees	醫院管理服務費	15,028	29,899	(14,871)	-49.7%
Third-party supply chain service fees	第三方供應鏈服務費	78,583	98,295	(19,712)	-20.1%
GPO gross profit	GPO毛利	70,715	76,639	(5,924)	-7.7%
Profit contribution	利潤貢獻合計	285,699	287,646	(1,947)	-0.7%
Operating expenses and other profit or loss	運營費用及其他損益	(21,050)	(18,293)	(2,757)	15.1%
Segment results	分部業績	264,649	269,353	(4,704)	-1.7%
Segment profit margin	分部利潤率	8.1%	8.8%	-0.7ppt	

Segment Results — IOT/OT Hospitals

The IOT/OT hospitals segment recorded respective increase in medical business revenue and results of 0.9% and 19.2% year-on-year.

分部業績 — IOT/OT醫院

IOT/OT醫院分部於報告期內的醫療業務收入和分部業績分別錄得同比增加0.9%和19.2%。

IOT/OT hospitals	IOT/OT醫院	Corresponding		Year-on-Year Change	
		2022H1 2022年 上半年	Period 相應期間	RMB'000 人民幣千元	RMB'000 人民幣千元
Revenue from medical business	醫療業務收入	729,766	723,559	6,207	0.9%
Hospital management services fees	醫院管理服務費	13,712	19,396	(5,684)	-29.3%
Third-party supply chain service fees	第三方供應鏈服務費	26,363	19,756	6,607	33.4%
GPO gross profit	GPO毛利	37,985	31,319	6,666	21.3%
Profit contribution	利潤貢獻合計	78,060	70,471	7,589	10.8%
Operating expenses and other profit or loss	運營費用及其他損益	(19,217)	(21,100)	1,883	-8.9%
Segment results	分部業績	58,843	49,371	9,472	19.2%
Segment profit margin	分部利潤率	8.1%	6.8%	1.3ppt	

Management Discussion and Analysis

管理層討論與分析

Headquarters operating expenses

During the Reporting Period, the total operating expenses of the headquarters amounted to approximately RMB36 million (Corresponding Period: approximately RMB61 million), accounting for 12.4% of the total administrative expenses of the Group (Corresponding Period: 32.5%). The decrease was mainly due to a sharp drop in staff costs after the reshaping of the organisation.

Other profit or loss

During the Reporting Period, other loss of the Group totaled approximately RMB16 million (Corresponding Period: other profit totaled approximately RMB14 million), which mainly included the income from bank financial products, and the change in the fair value of shares of UMP Healthcare Holdings as held by the Group and the exchange gains and losses. Among which, the recorded exchange loss due to changes in exchange rate during the Reporting Period was approximately RMB77 million.

Finance costs

During the Reporting Period, the finance cost of the Group amounted to approximately RMB12 million (Corresponding Period: approximately RMB5.9 million). The increase in the finance costs was in line with the increase in our loans.

Income tax expense

During the Reporting Period, the Group's income tax expenses amounted to approximately RMB39 million (the same period in 2021: approximately RMB65 million). The effective income tax rate of the Group's recurring business was 25.0% (Corresponding Period: 24.0%).

Net profit

The Group recorded a net profit of RMB215 million, representing a year-on-year increase of 4.6%.

總部運營費用

報告期內，總部運營費用合計約人民幣3,600萬元(相應期間：約人民幣6,100萬元)，佔本集團全部行政費用總數的12.4%(相應期間：32.5%)，乃由組織重塑後人工成本大幅下降所致。

其他損益

報告期內，本集團之其他損失合計約人民幣1,600萬元(相應期間：其他收益約人民幣1,400萬元)，主要包含銀行理財產品收益、本集團所持之聯合醫務集團股票其公允價值之變動及匯兌損益。當中報告期內因匯率變動產生的匯兌損失約為人民幣7,700萬元。

財務費用

報告期內，本集團之財務費用合計約為人民幣1,200萬元，(相應期間：約人民幣590萬元)，有關費用上升主要是由於銀行貸款總額增加所致。

所得稅費用

報告期內，本集團之所得稅費用約為人民幣3,900萬元(2021年同期：約人民幣6,500萬元)，本集團經常性業務的有效所得稅稅率為25.0%(相應期間：24.0%)。

淨利潤

本集團於報告期內錄得淨利潤人民幣2.15億元，同比增加4.6%。

SIGNIFICANT INVESTMENTS, ACQUISITIONS AND DISPOSALS, INVESTMENTS IN JOINT VENTURE(S) AND ASSOCIATE(S), AND SUBSEQUENT PLANS FOR MATERIAL CAPITAL INVESTMENTS

As at June 30, 2022, the Group did not have any significant investments. During the Reporting Period, the Group did not have any significant acquisitions and disposals of subsidiaries, associates or joint ventures.

Investment in UMP Healthcare Holdings

UMP Healthcare Holdings, listed on the main board of the Stock Exchange (stock code: 722.HK), is mainly engaged in providing healthcare solutions and service in Hong Kong. Details of investment in UMP Healthcare Holdings have been disclosed in the Company's annual reports in prior years. Pursuant to the relevant accounting standards, the Company has categorised the investment in UMP Healthcare Holdings as financial assets at fair value through profit or loss. As at June 30, 2022, the fair value of the investment in UMP Healthcare Holdings was approximately RMB58.88 million.

Investments in Associates — JR Renkang & JR Holdings

On June 28, 2020, the Group entered into a restructuring agreement on the establishment of two associates with Jing Mei Group, pursuant to which Beijing Jing Run Renkang Hospital Management Co., Ltd. ("**JR Renkang**") and Beijing Jing Run Renkang Holdings Co., Ltd. ("**JR Holdings**") were established and held by the Group and Jing Mei Group as to 49% and 51%, respectively. Upon establishment, JR Renkang and JR Holdings became associates of the Group. Pursuant to the abovementioned agreement, JR Holdings has become the sponsor of the Jing Mei Hospital Group and JR Renkang has been providing hospital management services to the Jing Mei Hospital Group. Please refer to the announcement of the Company dated June 28, 2020 for further details.

重大投資、收購和出售，於合資公司及聯營公司的投資，以及後續主要資本性投資計劃

於2022年6月30日，本集團並無任何重大投資。報告期內，本集團並無任何有關附屬公司、聯營公司或合營企業的重大收購及出售。

對聯合醫務集團的投資

聯合醫務集團為在聯交所主板上市的公司（股份代號：722.HK），致力於在香港提供醫療護理方案和服務。關於聯合醫務集團的投資細節已在本公司此前的年度報告中披露。根據適用的會計準則，本公司對聯合醫務集團投資獲劃分為以公允價值計量且其變動計入損益的金融資產。於2022年6月30日，對聯合醫務集團所持股權的公允價值約為人民幣5,888萬元。

於聯營公司 — 京潤仁康及京潤控股之投資

於2020年6月28日，本集團與京煤集團就成立兩間聯營公司訂立一份重組協議，雙方據此成立了北京京潤仁康醫院管理有限公司（「京潤仁康」）及北京京潤仁康控股有限公司（「京潤控股」），並由本集團及京煤集團分別持有49%及51%。成立後，京潤仁康及京潤控股成為本集團之聯營公司。根據上述協議之相關安排，京潤控股已成為京煤醫院集團之舉辦人，京潤仁康則向京煤醫院集團提供醫院管理服務。請參閱本公司日期為2020年6月28日之公告以了解進一步詳情。

Management Discussion and Analysis

管理層討論與分析

Future Plans for Material Investment or Capital Assets

As at the date of this report, there are currently no concrete plans to acquire any material investment or capital assets other than those conducted in the Group's ordinary course of business.

CONNECTED TRANSACTIONS

Withdrawal from CMH Fund

On February 14, 2022, Unison Champ Premium Limited (formerly known as Unison Champ Limited, which is a wholly-owned subsidiary of the Company, "**Unison Champ**") and the general partner (the "**General Partner**") of CMH Healthcare Fund, L.P. (the "**CMH Fund**") entered into a letter agreement (the "**Withdrawal Letter**"), pursuant to which Unison Champ requested the General Partner to consent to its withdrawal as a limited partner of the CMH Fund (the "**Limited Partner**") in whole from the CMH Fund (the "**Withdrawal**") and cancellation of its entire interests in the CMH Fund (the "**Cancellation of Interests**") and the General Partner has given its consent to the Withdrawal and the Cancellation of Interests. With effect from the date of the Withdrawal Letter: (i) the General Partner will effectuate the Withdrawal and the Cancellation of Interests pursuant to the relevant clause as set out in the corresponding limited partner agreement; (ii) Unison Champ will cease to be a Limited Partner and will no longer be entitled to any rights of a Limited Partner under the limited partner agreement; and (iii) the General Partner will have no claims or rights of whatsoever kind against Unison Champ, and not make further drawdowns from Unison Champ. The CMH Fund has not made any investment, and accordingly, no distribution and/or other proceeds has been made or distributed to its investors. As of the date of the Withdrawal Letter, other than the debts and liabilities already incurred and owed by the CMH Fund to third party service providers and agents, there is no unliquidated debts and liabilities of the CMH Fund. Pursuant to the Withdrawal Letter, Unison Champ shall not be liable to any expenses, costs or fees incurred exceeding its capital contribution in accordance with the proportion of capital commitment to the CMH Fund amounted to US\$617,933. Unison Champ's capital contribution which has not been used in the amount of US\$45,091 (the "**Contribution to be returned**") will be

未來重大投資或資本資產計劃

於本報告日期並無實際計劃收購任何重大投資或資本資產，惟循本集團日常業務進行者除外。

關連交易

退出CMH基金

和凱第一有限公司(前稱和凱有限公司，本公司之全資附屬公司，「和凱」)與CMH Healthcare Fund, L.P. (「CMH基金」)之普通合夥人(「普通合夥人」)於2022年2月14日簽訂了一份協議函件(「退出函」)，據此，和凱要求普通合夥人同意其終止彼之作為CMH基金有限合夥人身份(「有限合夥人」)並完全退出CMH基金(「退出安排」)及註銷彼在CMH基金中的全部權益(「權益註銷」)，而普通合夥人已同意退出安排及權益註銷。自退出函日期起：(i)普通合夥人將根據相關有限合夥人協議中規定的相關條款實施退出安排及權益註銷；(ii)和凱將不再作為有限合夥人，且不再享有有限合夥人在有限合夥人協議項下的任何權利；及(iii)普通合夥人不會對和凱提出任何類型的索賠或擁有任何類型的權限，並且不會向和凱作進一步請款。CMH基金尚無進行任何投資，因此亦無向其投資者作出或分配任何回報收益或其他收益。於退出函日期，除CMH基金已產生及應付第三方服務提供商及中介代理的債款及負債外，CMH基金無未清償的債款及負債。根據退出函，和凱無需承擔超過其對CMH基金617,933美元的按承諾注資金額的比例已出資金額外產生

returned by the General Partner to Unison Champ within 30 days upon the date of the Withdrawal Letter (which has already been settled as at the date of this report). Except for the amount of the Contribution to be returned, there is no other distribution or payment due and payable by the CMH Fund to Unison Champ and no other liabilities and obligations owed to Unison Champ by the CMH Fund, and Unison Champ is not entitled to any other payment from the assets of the CMH Fund in respect of the Withdrawal and/or the Cancellation of Interests. Please refer to the announcement of the Company dated February 14, 2022 for further details of the abovementioned arrangement.

FUTURE OUTLOOK

China Resources Medical will continue to implement the “Healthy China” development strategy. The ever improving medical technology of our member hospitals is our core capability. We will also continue to strengthen our advantageous specialties and leverage the synergy of the hospital groups of different regions. Our “RUNXIN” patient service system for patients will be further enhanced to gain prestige in respect of patient experiences and advance the “patient-oriented” culture of service. The operation and management system of our hospitals will be further modernized, refined and standardized in order to ensure efficient operation and improve the quality of our medical services. Hospitals of our Group are all connected online to encourage collaboration and further develop synergy. Through the aforesaid group level management and efficient supply chain, the sustainable development of the ecosystem of our business is ensured and our brand is shaped.

Following the normalisation of pandemic prevention and control, we shall accordingly explore different ways to further improve the efficiency of our operation and the quality of our medical services. Risks shall be effectively managed via thorough policy research on the reform of medical insurance payment and formulation of measures in a timely manner. We will also seize the window period for the reform of state-owned hospitals and the corresponding merger and acquisition opportunities so as to accelerate our extensional growth.

的任何支出、成本或費用。和凱出資金額中的未動用的45,091美元(「返還出資款」)將由普通合夥人在退出函簽署日起30天內返還予和凱(於本報告日期已返還)。除了返還出資款外，CMH基金不存在其他應支付予和凱的回報收益或款項，也不存在CMH基金對和凱承擔的其他責任和義務，且CMH基金無需在彼之資產中就其和凱的退出安排及／或權益註銷作出支付。關於上述安排，詳情可參閱本公司日期為2022年2月14日之公告。

未來展望

華潤醫療會持續踐行「健康中國」發展戰略，堅持以醫療技術提升為主線，構建業務核心能力；不斷建設區域領先的優勢學科和區域領先醫院群；深入推動「潤心」患者服務體系建設工作，實現「以病人為中心」的醫療服務人文關懷；持續加強醫院管理科學化、精細化、規範化，提高醫院經營管理效率與醫療服務品質，並借助互聯網等技術，提高地區內成員醫療機構間的協作效率。通過上述的集團化管理和全價值供應鏈的高效運營，實現生態圈的可持續發展，打造華潤醫療的醫療技術服務品牌。

在疫情防控常態化情況下，我們將持續探索提高醫院經營管理效率與醫療服務質素的路徑；加強對醫保支付改革的政策研讀，預判風險，及時制定應對舉措。我們也會搶抓國企醫院改革窗口期，對短缺領域的醫療機構保持關注，外延增長可期。

Management Discussion and Analysis

管理層討論與分析

FINANCIAL REVIEW

Liquidity and Financing

We adopt a prudent treasury management policy to maintain a solid and healthy financial position. The Group funds its operations principally from cash generated from its operations and bank facilities. Its cash requirements relate primarily to operating activities, business expansion, repayment of liabilities as they become due, capital expenditures, interest and dividend payments.

As at June 30, 2022, the Group's consolidated bank balances and cash, time deposits and bank financial products amounted to approximately RMB3.35 billion in total (December 31, 2021: approximately RMB3.23 billion) which were primarily denominated in RMB.

As at June 30, 2022, the Group has obtained offshore revolving term loan facility of HK\$5.2 billion (or its equivalent in U.S. dollar or RMB). Among which, HK\$1.1 billion of the facility is a five-year committed loan, HK\$3 billion of the facility is with no fixed term until further notice by the corresponding bank, whilst the remaining HK\$1.1 billion of the facility is of the term of one year which shall be automatically renewed if the relevant bank does not notify otherwise. As at June 30, 2022, the Group had interest-bearing bank borrowings of approximately HK\$2.04 billion (equivalent to approximately RMB1.74 billion) (December 31, 2021: approximately HK\$933 million and US\$139 million (equivalent to approximately RMB1.65 billion)), and unutilized bank facilities of approximately HK\$3.16 billion (equivalent to approximately RMB2.70 billion). As at June 30, 2022, the Group's offshore bank borrowings carried interests at floating rates, among which, HK\$1.1 billion would be due on June 25, 2027, and others would be due within one year. HK\$0.7 billion of the facilities is the sustainability-linked and social loan.

As at June 30, 2022, on the basis of interest-bearing liabilities (excluding payables to the Sponsored Hospitals and lease liabilities) divided by total assets, the Group's gearing ratio was 16.0% (December 31, 2021: 15.9%). In addition, the carrying value of each of our wealth management products as at June 30, 2022 did not exceed 5% of the Group's total asset value.

財務回顧

資金及融資

我們採取審慎財務管理政策以維持健全財務狀況。本集團主要透過營運產生之資金及銀行授信為營運提供資金。本集團現金需求主要與經營活動、業務拓展、償還到期負債、資本支出、利息及股息派付有關。

於2022年6月30日，本集團綜合銀行結餘及現金、定期存款及銀行理財產品合計約人民幣33.5億元（2021年12月31日：約人民幣32.3億元），其主要以人民幣計值。

於2022年6月30日，本集團於境外獲銀行提供的循環貸款授信總額為52億港元（或等值美元／人民幣）；當中11億港元額度為五年期承諾性貸款，30億港元額度其直至相關銀行另行通知為止為無固定期限，其餘11億港元額度為一年期及如相關銀行無另行通知則自動續期。於2022年6月30日，本集團擁有計息銀行貸款約為20.4億港元（約合人民幣17.4億元）（2021年12月31日：約9.33億港元及1.39億美元（約合人民幣16.5億元）），未使用銀行授信額度約為31.6億港元（約合人民幣27.04億元）。於2022年6月30日，本集團之境外銀行貸款按浮動利率計息，其中11億港元境外銀行貸款將於2027年6月25日到期，剩餘貸款將於一年內到期。本集團有7億港元貸款為社會責任貸款兼可持續發展關聯貸款。

於2022年6月30日，按有息負債（不含應付舉辦權醫院款項以及租賃負債）除以總資產的基準計算，本集團的槓桿比率為16.0%（2021年12月31日：15.9%）。另外，於2022年6月30日，我們每項理財產品的賬面價值均不超過本集團總資產價值的5%。

Exposure to Fluctuation in Exchange Rates, the Interest Rate Risk and Other Risks

The Group undertakes certain operating transactions in foreign currencies, which exposes the Group to foreign currency risk, mainly pertaining to the risk of fluctuations in the Hong Kong dollar and U.S. dollar against RMB.

The Group has not used any derivative contracts to hedge against its exposure to currency risk. The management manages the currency risk by closely monitoring the movement of the foreign currency rates and considers hedging against significant foreign exchange exposure should such need arise.

We are also exposed to risk of talent shortage, so we have been taking an active approach to attract, train and retain sufficient qualified doctors, management personnel and other medical staff members, otherwise the business of hospitals affiliated to the Group would be affected to a certain extent. Please refer to the paragraph headed “Management Discussion and Analysis — Employees and Remuneration Policy” for those measures mentioned above.

We also recognise that our relationship with patients and partners is key to the resilient development of the Group. We strive to provide quality services and medical staffs with extensive experiences to our patients. By leveraging on sophisticated medical skills and equipment, we try our best to cater to our patients’ needs for medical treatments. We also cooperate with our partners to achieve the sustainable development of our business.

Contingent Liabilities

As at June 30, 2022, the Group did not have any contingent liabilities or guarantees that would have a material impact on the financial position or operations of the Group.

Pledge of Assets

As of June 30, 2022, the Group did not have any material pledge of assets.

匯率波動風險、利率風險及其他風險

本集團以外幣訂立若干營運交易協議，主要涉及港元和美元兌人民幣的匯率波動風險，本集團因此面臨外匯風險。

本集團未使用任何衍生合約對沖貨幣風險。管理層透過密切監控外匯匯率變動來管理貨幣風險，若出現相關需求，管理層亦考慮對重大外匯風險進行對沖。

我們亦面對人才短缺風險，故一直積極採取相應措施以吸引、培訓及挽留足夠的合資格醫生、管理人員和其他醫護人員，否則我們下屬的醫院業務將受到一定的影響。上述措施詳見本報告「管理層討論與分析 — 僱員及薪酬政策」段落。

我們亦深知與病人及合作夥伴的關係是本集團業務穩健發展的關鍵。我們致力為病人提供優質服務，為病人配備經驗豐富的醫護人員，運用成熟的醫療技術和設備，盡力滿足病人的醫療需要。我們亦與合作夥伴協力同心，以實現我們業務的可持續發展。

或有負債

於2022年6月30日，本集團並無擁有任何會對本集團財務狀況或營運產生重大影響的或有負債或擔保。

資產抵押

於2022年6月30日，本集團無任何重大資產抵押。

Management Discussion and Analysis

管理層討論與分析

Employees and Remuneration Policy

As of June 30, 2022, the Group had a total of 9,866 full-time employees (December 31, 2021: 8,454 employees). For the Reporting Period, the staff costs (including Directors' remuneration in the form of salaries and other benefits) was approximately RMB836 million (Corresponding Period: RMB471 million).

The Group ensured that the remuneration packages of employees remain competitive and the remuneration level of its employees was determined on the basis of performance with reference to the profitability of the Group, industry remuneration standards and market conditions within the general framework of the Group's remuneration system.

The Group has also adopted the Share Option Scheme and the Share Award Scheme so as to provide incentives or rewards to Eligible Persons for their contribution or potential contribution to the Company and/or any of its subsidiaries.

Contractual Obligations

As at June 30, 2022, the Group did not have any significant contractual obligations that would have a material effect on the financial position or operations of the Group.

Financial Instruments

The Group's major financial instruments include trade and bills receivables, amounts due from related parties, receivables from IOT Hospitals, other receivables, financial assets at fair value through profit or loss, other financial assets at amortised cost (All of them are fixed deposits in nature, and certain of their deposit periods are longer than 1 year), cash and cash equivalents, restricted and pledged bank deposits, trade and bills payables, amount due to related parties, payables to the Sponsored Hospitals, other payables and interest bearing bank and other borrowings. The risks associated with these financial instruments include market risk, credit risk and liquidity risk. The management manages and monitors these exposures to ensure appropriate measures are implemented on a timely and effective manner.

Interim Dividend

The Board did not recommend the payment of any interim dividend for the Reporting Period (Corresponding Period: nil).

Events After The Reporting Period

There were no important events affecting the Group after June 30, 2022.

僱員及薪酬政策

於2022年6月30日，本集團合共擁有9,866名全職僱員(2021年12月31日：8,454名僱員)。於報告期，僱員成本(包括薪金及其他福利形式的董事薪酬)約為人民幣8.36億元(相應期間：人民幣4.71億元)。

本集團確保僱員薪酬福利方案具競爭力，僱員的薪酬水平乃經參考本集團盈利能力、同行同業薪酬水平及市場環境後於本集團的一般薪酬制度架構內按工作表現釐定。

本集團亦已採納購股權計劃及股份獎勵計劃以向合資格人士就其為本公司及／或其任何附屬公司作出的貢獻或可能作出的貢獻提供獎勵或回報。

合同義務

於2022年6月30日，本集團概無任何重大合同義務會對本集團的財務狀況或營運造成重大影響。

金融工具

本集團的主要金融工具包括應收貿易款項及應收票據、應收關聯方款項、應收IOT醫院款項、其他應收款項、以公允價值計量且其變動計入損益的金融資產、其他按攤銷成本計量的金融資產(性質上全數為定期存款，當中部分存款期長於1年)、現金及現金等價物、限制性及已抵押銀行存款、應付貿易款項及應付票據、應付關聯方款項、應付舉辦權醫院款項、其他應付款項及計息銀行及其他借款。與該等金融工具相關的風險包括市場風險、信用風險及流動性風險。管理層管理及監察該等風險，以確保及時採取有效措施。

中期股息

董事會不建議就報告期派付中期股息(相應期間：無)。

報告期後事項

於2022年6月30日後，概無影響本集團的重要事項。

Corporate Governance Highlights

企業管治摘要

Compliance with the CG Code

The Company confirms that it has complied with all material code provisions of the CG Code contained in Appendix 14 to the Listing Rules during the Reporting Period.

The Board will review the corporate governance structure and practices from time to time and shall make necessary arrangements when the Board considers appropriate.

Model Code for Securities Transactions by Directors

The Company has adopted the Model Code as its own code of conduct for dealing in securities of the Company by the Directors. Having made specific enquiry with all Directors, the Company confirmed that all Directors complied with the Model Code throughout the Reporting Period under review. Senior management, executives and staff who, because of their offices in the Company, are likely to possess inside information of the Company have also been requested to comply with the provisions of the Model Code and the Company confirmed that there was no incident of non-compliance of the Model Code by such employees throughout the Reporting Period.

Review of Interim Results

The Audit Committee has reviewed the unaudited consolidated interim results of the Group for the Reporting Period under review and considered that they were prepared in compliance with the relevant accounting standards, the Listing Rules and the applicable legal requirements, and that the Company has made appropriate disclosure thereof.

In addition, the unaudited consolidated interim results of the Group for the Reporting Period under review have been reviewed by the external auditors of the Company.

Risk Management and Internal Control

The risk management and internal control systems have been designed to protect the assets of the Group, to ensure the proper maintenance of accounting records, and to ensure the compliance with the relevant laws and regulations.

遵守企業管治守則

本公司確認，於報告期內其已遵守上市規則附錄14所載之企業管治守則之所有重大守則條文。

董事會將不時審閱企業管治架構及常規，並於其認為適當時作出必要安排。

董事進行證券交易的標準守則

本公司已採納標準守則作為董事買賣本公司證券的行為守則。經對所有董事作出具體查詢後，本公司確認所有董事於整段報告期內均遵守標準守則。基於高級管理層、高級行政人員及高級職員於本公司的職務，彼等可能擁有本公司的內部資料，亦須遵守標準守則的條文，且本公司確認，並無該等僱員於整段報告期內未有遵守標準守則的事件。

審閱中期業績

審核委員會已審閱本集團報告期之未經審核綜合中期業績，並認為該等中期業績已根據有關會計準則、上市規則及適用法律規定編製，且本公司已作出適當披露。

另外，本集團報告期之未經審核綜合中期業績已經本公司外聘核數師審閱。

風險管理及內部監控

風險管理及內部監控制度的制訂旨在保障本集團資產、確保妥為存置會計記錄及確保遵守有關法律法規。

Corporate Governance Highlights

企業管治摘要

The Board has overall responsibility for maintaining a sound and effective risk management and internal control systems of the Group in general which includes a clearly defined management structure with limits of authority, and is designed to ensure the proper application of accounting standards, the provision of reliable financial information for internal use and publication, and to secure compliance with the relevant laws and regulations. Such systems are developed to provide reasonable, but not absolute assurance against material misstatement or omission and to manage, but not fully eliminate, the risks of operational systems failure and the risks of the Group's failure in meeting the standards. The Board will review the risk management and internal control systems on an on-going basis.

During the Reporting Period, the Board has performed a review on the efficiency of the Group's risk management and internal control systems on different aspects of the Group such as financial, operation, compliance and risk management, and has also assessed the accounting and financial reporting functions of the Group, estimated the resources and budgets for training programmes and reviewed the qualifications and experience of staff members.

The Board considers that the current risk management and internal control systems cover the existing businesses of the Group, and will continue to be optimized in line with the business development of the Group.

In particular, the Board will devote efforts in complying with the Listing Rules, ensuring compliance with the relevant laws and regulations and safeguarding the interests of the Shareholders as a whole.

Changes in Directors' Information

Changes in Directors' information since the date of the 2021 annual report of the Company which is required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules are set out below:

Mr. WU Ting Yuk, Anthony resigned as the independent non-executive director of Guangdong Investment Limited (which is listed on the main board of the Stock Exchange, stock code: 270.HK) with effect from June 23, 2022.

董事會負整體責任維持本集團整體的良好有效風險管理及內部監控制度，當中包括設有權力限制的明確管理架構，旨在確保妥為應用會計準則以及提供可靠財務資料作內部使用及刊發用途，並確保符合相關法律法規。該制度的建立是杜絕重大錯誤陳述或遺漏提供合理而非絕對保證，並管理而非全面消除營運系統故障的風險，以及本集團未能符合標準的風險。董事會將持續檢討風險管理及內部監控制度。

報告期內，董事會已就財務、營運、合規及風險管理等本集團不同範疇對本集團風險管理及內部監控制度的效率進行檢討，亦已評估本集團會計及財務報告職能、估計培訓課程的資源及預算，並核證員工的資格及經驗。

董事會認為，目前的風險管理及內部監控制度已涵蓋本集團現有業務，並將持續根據本集團的業務發展完善。

尤其是在遵守上市規則、遵守相關法律及法規、維護整體股東權益方面，董事會將會作出努力。

董事資料變更

自本公司2021年年報日期以來，根據《上市規則》第13.51B(1)條所須披露之本公司董事資料的變更載列如下：

胡定旭先生辭任粵海投資有限公司（該公司於聯交所主板上市，股票代號：270.HK）之獨立非執行董事職務，自2022年6月23日起生效。

Sponsorship Rights, Service Contracts and Goodwill

The amendments to the respective constitutional documents of the member medical institutions, which are sponsored by our subsidiaries, have been completed pursuant to the requirements under the 'Guiding Opinions on the Pilot Scheme for the Formulation of Hospital Constitutions' jointly issued by the National Health Commission and the National Administration of Traditional Chinese Medicine in May 2018, the model template of public hospital constitution issued by the National Health Commission in December 2019 and the guidelines given by the respective local government authorities. As such, the Group has therefore obtained the practical capability to direct the relevant activities of such medical institutes unilaterally and gained control over them, and their financial statements have therefore gradually been consolidated into the Group's financial statements in 2020 and 2021. Due to the above consolidation, the Group no longer records any sponsorship rights and service contracts related to such sponsored hospitals in the consolidated statement of financial position as at December 31, 2021.

Management of the Company performed impairment reviews of sponsorship rights, service contracts and goodwill annually or more frequently if events or changes in circumstances indicated a potential impairment. The recoverable amounts of the abovementioned sponsorship rights, service contracts and goodwill were determined based on the fair value under income approach less costs of disposal. These calculations required the use of estimates and professional judgments, and management of the Company involved an external valuer in these calculations. Based on the management's assessment, no impairment was required on the abovementioned sponsorship rights, service contracts and goodwill as at June 30, 2022.

舉辦權、服務合同及商譽

根據國家衛生健康委員會和國家中醫藥管理局在2018年5月聯合下發的《關於開展制定醫院章程試點工作的指導意見》、國家衛生健康委員會於2019年12月下發的公立醫院章程範本，以及各下屬成員醫療機構所在地的相關政府部門所給予的指引，由本集團附屬公司所舉辦的成員醫療機構已按照要求完成相關章程修訂工作，本集團因此已具備獨立指導有關醫療機構相關活動及控制上述醫療機構的實際能力，彼等之財務報表亦因此於2020年及2021年逐步併入本集團的財務報表內。因應上述併表安排，本集團於2021年12月31日及其後的綜合財務狀況報表上不再錄有舉辦權及該等舉辦權醫院相關之服務合同項目。

本公司管理層對舉辦權、服務合同及商譽進行減值審查，一般而言每年進行，如有任何事件或情況變化可能導致潛在的減值則有關的審查會更頻繁地進行。上述舉辦權、服務合同及商譽的可收回金額乃據使用收益法下釐定的公允價值減去出售成本計算而得。鑒於有關的計算需要預估和專業判斷，本公司管理層聘請外部估值師進行相關計算。根據管理層判定，截至2022年6月30日上述舉辦權、服務合同及商譽無需計提減值。

Other Information

其他資料

Yan Hua IOT Agreement Dispute

On January 21, 2019, the Company received a letter from Yan Hua Phoenix and Yan Hua Hospital (“Yan Hua”) to unilaterally terminate the Yan Hua IOT Agreement with effect from January 21, 2019. On April 17, 2019, the Group has submitted a civil claim statement against Yan Hua Phoenix and Yan Hua Hospital in relation to the Yan Hua IOT Agreement dispute to Beijing Second Intermediate People’s Court to seek the court’s ruling that the unilateral termination of Yan Hua IOT Agreement by Yan Hua Phoenix and Yan Hua Hospital on January 21, 2019 shall be void and that Yan Hua Phoenix and Yan Hua Hospital should be liable for damages for breach of the Yan Hua IOT Agreement. On December 18, 2019, the Beijing Second Intermediate People’s Court handed down the civil judgment ([2019] Jing 02 Minchu No.304) and the major details are as follows: (1) the unilateral termination of Yan Hua IOT Agreement by Yan Hua Phoenix and Yan Hua Hospital is declared to be void and that the parties shall continue to perform its obligations under the Yan Hua IOT Agreement; (2) the amount of RMB14,400,000, being the damages for breach of the Yan Hua IOT Agreement, is to be paid by Yan Hua Phoenix to CR Hospital Management & Consulting; (3) other reliefs sought by CR Hospital Management & Consulting shall be dismissed; and (4) other counterclaims of Yan Hua Phoenix and Yan Hua Hospital shall be dismissed. In January 2020, Yan Hua Phoenix and Yan Hua Hospital filed an appeal on the Original Judgment to Beijing Higher People’s Court, and the relevant court hearing was held on October 26, 2020. On November 22, 2021, the Beijing Higher People’s Court handed down a civil judgment (2020 Jing Minzhong No.110) which rejected the abovementioned appeal filed by Yan Hua Phoenix and Yan Hua Hospital and upheld the Original Judgment, and adjudged that such ruling shall be final. The Company filed an application for the enforcement of the final judgment to Beijing Second Intermediate People’s Court in January 2022, and the court accepted the Company’s application for enforcement in February 2022. As of the date of this report, the Company has received the ascertained damages of RMB14,400,000 paid by Yan Hua Phoenix according to the final judgment and will continue to urge Yan Hua to perform the final judgment. The Company will continue using its best endeavors and taking all appropriate actions to protect the interests of the Company and the Shareholders. The Company will make further announcement in accordance with the Listing Rules as and when appropriate for the future progress of the Yan Hua IOT Agreement dispute. Please refer to the announcements published by the Company on January 15, 2019, January 21, 2019, April 17, 2019 and November 23, 2021 for more details.

燕化IOT協議爭議

於2019年1月21日，本公司收到燕化鳳凰及燕化醫院（「燕化方」）之信函通知其自2019年1月21日起單方面終止燕化IOT協議。本集團已於2019年4月17日就燕化IOT協議爭議向北京市第二中級人民法院遞交民事起訴狀起訴燕化鳳凰及燕化醫院，請求法院判定燕化鳳凰及燕化醫院於2019年1月21日單方面解除燕化IOT協議的行為無效，以及燕化鳳凰及燕化醫院須支付其因違反燕化IOT協議所造成的違約損失。於2019年12月18日，北京市第二中級人民法院作出（民事判決書[2019]京02民初第304號）民事判決，主要內容如下：(1)宣告燕化鳳凰及燕化醫院單方面對《燕化IOT協議》作出的終止為無效，及雙方應繼續履行《燕化IOT協議》項下的義務；(2)由燕化鳳凰向華潤醫院管理諮詢支付金額為人民幣14,400,000元的因違反《燕化IOT協議》引起的損害賠償；(3)駁回華潤醫院管理諮詢尋求的其他賠償；及(4)駁回燕化鳳凰和燕化醫院的反訴。於2020年1月，燕化鳳凰和燕化醫院向北京市高級人民法院就原判決提出上訴，並已於2020年10月26日開庭審理。於2021年11月22日，北京市高級人民法院作出2020京民終110號民事判決，駁回上述燕化鳳凰和燕化醫院的上訴、維持原判決，並裁定此判決為終審判決。本公司已於2022年1月向北京市第二中級人民法院提出了執行終審判決的申請，而該法院於2022年2月受理了本公司的執行申請。截止本報告刊發之日，本公司已收到燕化鳳凰根據終審判決應支付的人民幣14,400,000元的違約金，並將繼續督促燕化方履行終審判決。本公司將會繼續盡最大努力及採取所有適當行動以保障本公司及股東的利益。就燕化IOT協議爭議的未來進展，本公司將會根據上市規則中的相關規定適時作出進一步公告。上述事項之詳情請參閱本公司於2019年1月15日、2019年1月21日、2019年4月17日及2021年11月23日刊發之公告。

Share Option Scheme

The Group has adopted a Share Option Scheme (pursuant to a resolution passed by the Shareholders on September 30, 2013) so as to provide incentives or rewards to Eligible Persons for their contribution or potential contribution to the Company and/or any of its subsidiaries.

During the Reporting Period, no share option was granted, exercised, cancelled or lapsed and there was no outstanding share option under the Share Option Scheme.

Share Award Scheme

The Company has adopted the Share Award Scheme as a means to recognise the contribution of and provide incentives for the key management personnel including Directors and senior management, employed experts and core employees of the Group. The Share Award Scheme shall be valid and effective for a period of 10 years commencing from July 7, 2014 (the “**Adoption Date**”) on which the Board adopted the Share Award Scheme and is administrated by the Board and the trustee of the Share Award Scheme. The Board resolved on May 25, 2015 to make amendments to the terms of the Share Award Scheme and the corresponding scheme rules, having retrospective effect from the Adoption Date.

The Board also resolved on August 31, 2018 to make further amendments to the terms of the Share Award Scheme to the effect that the maximum number of the Award Shares, which have been and to be awarded by the Board throughout the duration of the Scheme, to be revised to 5% of the total number of issued Shares of the Company as at the date of the abovementioned Board resolution and the maximum number of the Award Shares to each of the Selected Participants to be revised to 1% of the total number of issued Shares as at the date of the abovementioned Board resolution.

購股權計劃

本集團根據股東於2013年9月30日通過的一項決議案採納購股權計劃以向合資格人士就其為本公司及／或其任何附屬公司作出的貢獻或可能作出的貢獻提供獎勵或回報。

報告期內概無購股權已授出、行使、取消或失效，以及概無根據購股權計劃尚未行使的購股權。

股份獎勵計劃

本公司已採納股份獎勵計劃作為嘉許本集團主要管理人員（包括董事及高級管理層）、僱用專家及核心僱員所作出的貢獻及為彼等提供獎勵的方式。股份獎勵計劃自2014年7月7日（「採納日期」），即董事會採納股份獎勵計劃之日期起計10年期間有效及生效，並由董事會及股份獎勵計劃的受託人管理。董事會於2015年5月25日議決修訂股份獎勵計劃之條款及相關之計劃規則，自採納日期起追溯生效。

董事會亦於2018年8月31日議決進一步修訂股份獎勵計劃之條款，經修訂後，董事會於整段計劃期間授出的獎勵股份總數上限重訂為本公司於董事會議決當天已發行股份總數的5%，且向各獲選參與者授出獎勵股份的總數上限重訂為本公司於董事會議決當天已發行股份總數的1%。

Other Information

其他資料

The Board will implement the Share Award Scheme in accordance with the scheme rules of Share Award Scheme. The Company shall comply with the relevant Listing Rules when granting the Award Shares.

Since the Adoption Date of Share Award Scheme and up to June 30, 2022, an aggregate of 32,212,216 Award Shares were granted pursuant to the Share Award Scheme subject to certain vesting criteria and conditions.

Issuance of Equity Securities

During the Reporting Period, the Company did not issue any equity securities (including securities convertible into equity securities) for cash.

Directors' and Chief Executives' Interests and Short Positions in Shares, Underlying Shares and Debentures of the Company or its Associated Corporations

As at June 30, 2022, the interests/short positions of the Directors and the chief executives of the Company in the shares, underlying shares and debentures of the Company or its associated corporations (within the meaning of Part XV of the SFO which were required (a) to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they are taken or deemed to have under such provisions of the SFO); or (b) to be entered into the register required to be kept by the Company pursuant to Section 352 of the SFO; or (c) as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers (i.e. the Model Code) set out in Appendix 10 to the Listing Rules were as follows:

董事會將根據股份獎勵計劃之規則實施該計劃。本公司於授出獎勵股份時應遵守相關上市規則。

自股份獎勵計劃的採納日期起並截至2022年6月30日，根據股份獎勵計劃合共授出32,212,216股獎勵股份，惟須受若干歸屬標準及條件所限。

發行股本證券

報告期內，本公司無發行任何股本證券(包括可轉換為股本證券的證券)以換取現金。

董事及最高行政人員於本公司或其相聯法團股份、相關股份及債券之權益及淡倉

截至2022年6月30日，本公司董事及最高行政人員於本公司或其相聯法團(定義見證券及期貨條例第XV部)之股份、相關股份及債權證中擁有(a)根據證券及期貨條例第XV部第7及第8分部須知會本公司及聯交所(包括彼等根據證券及期貨條例之該等條文被視為或被當作擁有的權益或淡倉)；或(b)須列入由本公司按證券及期貨條例第352條存置之登記冊內；或(c)根據上市規則附錄十所載上市發行人董事進行證券交易的標準守則(即標準守則)須知會本公司及聯交所之任何權益/淡倉如下：

Interests/short positions in Shares of the Company 於本公司股份的權益／淡倉

Name of Director 董事姓名	Capacity/ Nature of interest 身份／權益性質	Long position/ short position 好倉／淡倉	Number of ordinary shares (Note) 普通股股份數目 (附註)	Approximate percentage of shareholding 持股概約百分比 %
SONG Qing 宋清	Beneficial owner 實益擁有人	Long position 好倉	400,000	0.03
CHENG Libing 成立兵	Beneficial owner 實益擁有人	Long position 好倉	1,774,746	0.14
REN Yuan 任遠	Beneficial owner 實益擁有人	Long position 好倉	300,000	0.02
WU Ting Yuk, Anthony 胡定旭	Beneficial owner 實益擁有人	Long position 好倉	1,000,000	0.08

Note: This includes also the long positions of the Award Shares, which have been declared to be granted by the Company to the corresponding Directors on August 31, 2018 and part of the declared Award Shares have been vested.

註：當中包括本公司於2018年8月31日宣告授予相關董事之獎勵股份所產生的好倉，而部份獎勵股份已授出。

Save as disclosed above, as at June 30, 2022, so far as it is known to the Directors or chief executives of the Company, none of the Directors or chief executives of the Company had any interests/short positions in the shares, underlying shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which were required (a) to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they were taken or deemed to have under such provisions of the SFO); or (b) to be entered into the register required to be kept by the Company pursuant to section 352 of the SFO; or (c) as otherwise to be notified to the Company and the Stock Exchange pursuant to the Model Code.

除上述披露者外，於2022年6月30日，據本公司董事或最高行政人員所知，概無本公司董事或最高行政人員於本公司或其任何相聯法團（定義見證券及期貨條例第XV部）之股份、相關股份及債券中擁有(a)根據證券及期貨條例第XV部第7及第8分部須知會本公司及聯交所（包括彼等根據證券及期貨條例之該等條文被視為或被當作擁有的權益或淡倉）；或(b)須列入由本公司按證券及期貨條例第352條存置之登記冊內；或(c)根據標準守則須知會本公司及聯交所之任何權益／淡倉。

Other Information

其他資料

Interests of Substantial Shareholders and Other Persons in Shares and Underlying Shares

As at June 30, 2022, the following persons (other than the Directors and chief executives of the Company) had or were deemed or taken to have an interest and/ or short position in the shares or the underlying shares which would fall to be disclosed under the provisions of Divisions 2 and 3 of Part XV of the SFO and as recorded in the register required to be kept by the Company under section 336 of the SFO, or who was, directly or indirectly, interested in 5% or more of the issued Shares of the Company.

主要股東及其他人士於股份及相關股份之權益

於2022年6月30日，以下人士（不包括本公司董事及主要行政人員）於股份或相關股份中擁有或被視為或被當作擁有根據證券及期貨條例第XV部第2及3分部之條文須予披露及記錄於本公司根據證券及期貨條例第336條規定存置之登記冊內之權益及／或淡倉，或直接或間接擁有本公司已發行股份中5%或以上的權益。

Name of Shareholder 股東名稱	Capacity/Nature of interest 身份／權益性質	Number of Shares held 持有股份數目	Approximate percentage of shareholding 持股概約百分比 %
China Resources Company Limited 中國華潤有限公司	Interest of a controlled corporation 受控法團權益	474,319,516(L) ⁽¹⁾	36.58
Mitsubishi UFJ Financial Group, Inc. 三菱日聯金融集團	Interest of a controlled corporation 受控法團權益	77,645,666(L) ⁽²⁾	5.98

L: Long position

L: 好倉

Notes:

附註：

- (1) (a) 463,681,516 of these shares are directly held by CRH (Medical) Limited. CRH (Medical) Limited is wholly owned by China Resources Healthcare Group Limited. China Resources Healthcare Group Limited is wholly owned by CRH (Healthcare) Limited. CRH (Healthcare) Limited is wholly owned by China Resources (Holdings) Company Limited. China Resources (Holdings) Company Limited is wholly owned by CRC Bluesky Limited. CRC Bluesky Limited is wholly owned by China Resources Inc. China Resources Inc. is wholly owned by China Resources Company Limited; and (b) 10,638,000 of these shares are directly held by Commotra Company Limited which is wholly owned by China Resources (Holdings) Company Limited.
- (2) Mitsubishi UFJ Financial Group, Inc. is the sole shareholder of Mitsubishi UFJ Trust and Banking Corporation whilst the latter is directly holding the entire shareholding interest in Carol Australia Holdings Pty Limited. Carol Australia Holdings Pty Limited (via its wholly-owned subsidiary First State Investment Managers (Asia) Limited) held the entire interest in First State Investments (Hong Kong) Limited and the latter directly held 77,645,666 Shares (representing 5.98% of the issued Shares of the Company).

- (1) (a) 其中該等463,681,516股股份由華潤集團(醫療)有限公司直接持有。華潤集團(醫療)有限公司由華潤健康集團有限公司全資擁有。華潤健康集團有限公司由華潤集團(健康)有限公司全資擁有。華潤集團(健康)有限公司由華潤(集團)有限公司全資擁有。華潤(集團)有限公司由CRC Bluesky Limited全資擁有。CRC Bluesky Limited由華潤股份有限公司全資擁有。華潤股份有限公司由中國華潤有限公司全資擁有；及(b)其中該等10,638,000股股份由合貿有限公司直接持有，而合貿有限公司由華潤(集團)有限公司全資擁有。
- (2) 三菱日聯金融集團為三菱日聯信託銀行的唯一股東，而後者則直接持有Carol Australia Holdings Pty Limited全數股權。Carol Australia Holdings Pty Limited(透過其全資附屬公司First State Investment Managers (Asia) Limited)持有First State Investments (Hong Kong) Limited全數權益，而後者則直接持有77,645,666股股份(佔本公司已發行股份數目的5.98%)。

Save as disclosed above, as at June 30, 2022, the Directors have not been notified by any person (other than the Directors or chief executives of the Company) who had interests or short position in the shares or underlying shares of the Company as recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO.

Purchase, Sale or Redemption of the Company's Listed Securities

For the Reporting Period, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities.

Sufficiency of the Public Float

Based on the information publicly available and to the best knowledge, information and belief of the Directors, the Directors confirm that the Company had maintained a sufficient public float as required under the Listing Rules throughout the Reporting Period.

On behalf of the Board
CHENG Libing
Executive Director and Chief Executive Officer

Beijing, August 23, 2022

除上述披露者外，於2022年6月30日，董事並無知悉任何人士（不包括本公司董事或最高行政人員）於本公司股份或相關股份中擁有記載於本公司根據證券及期貨條例第336條須存置之登記冊內的權益或淡倉。

購買、出售或贖回本公司上市證券

報告期，本公司或其任何附屬公司概無購買、出售或贖回本公司任何上市證券。

足夠的公眾持股量

根據公開可獲得的資料及據董事所深知、盡悉及確信，董事確認，本公司於報告期內一直維持上市規則規定之足夠的公眾持股量。

代表董事會
執行董事及總裁
成立兵

北京，2022年8月23日

Independent Review Report

獨立審閱報告



To the board of directors of China Resources Medical Holdings Company Limited

(Incorporated in the Cayman Islands with limited liability)

Introduction

We have reviewed the interim financial information set out on pages 30 to 74, which comprises the condensed consolidated statement of financial position of China Resources Medical Holdings Company Limited (the “Company”) and its subsidiaries (the “Group”) as at 30 June 2022 and the related condensed consolidated statements of profit or loss and other comprehensive income, changes in equity and cash flows for the six-month period then ended, and explanatory notes. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of a report on interim financial information to be in compliance with the relevant provisions thereof and International Accounting Standard 34 *Interim Financial Reporting* (“IAS 34”) issued by the International Accounting Standards Board. The directors of the Company are responsible for the preparation and presentation of this interim financial information in accordance with IAS 34. Our responsibility is to express a conclusion on this interim financial information based on our review. Our report is made solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

致華潤醫療控股有限公司董事會

(於開曼群島註冊成立的有限公司)

緒言

吾等已審閱載於第30頁至第74頁之華潤醫療控股有限公司(「貴公司」)及其附屬公司(統稱「貴集團」)之中期財務資料，此等中期財務資料包括於2022年6月30日之簡明綜合財務狀況報表及截至該日止六個月期間之相關簡明綜合損益及其他全面收益報表、簡明綜合權益變動報表及簡明綜合現金流量報表，以及其他說明附註。香港聯合交易所有限公司證券上市規則要求按照上市規則的相關條文及國際會計準則理事會頒佈之國際會計準則第34號*中期財務報告*(「國際會計準則第34號」)就中期財務資料編製報告。貴公司董事負責根據國際會計準則第34號編製及呈列本中期財務資料。吾等責任為根據審閱之結果，對本中期財務資料作出結論，並根據協定之聘用條款僅向閣下(作為整體)作出報告，除此之外本報告並無其他用途。吾等概不就本報告之內容對任何其他人士負責或承擔任何責任。

Scope of Review

We conducted our review in accordance with Hong Kong Standard on Review Engagements 2410 *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Hong Kong Institute of Certified Public Accountants. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the interim financial information is not prepared, in all material respects, in accordance with IAS 34.

Ernst & Young

Certified Public Accountants
27/F, One Taikoo Place
979 King's Road
Quarry Bay
Hong Kong

23 August 2022

審閱範圍

吾等已按照香港會計師公會頒佈之香港審閱工作準則第2410號實體的獨立核數師對中期財務資料的審閱進行審閱工作。中期財務資料審閱工作主要包括向負責財務和會計事務的人員作出查詢，及進行分析性和其他審閱程序。審閱的範圍遠小於根據香港審計準則進行審計的範圍，故不能令吾等保證吾等將知悉在審計中可能被發現的所有重大事項。因此，吾等不會發表審計意見。

結論

按照吾等的審閱，吾等並無發現有任何事項導致吾等相信中期財務資料在各重大方面未有按照國際會計準則第34號編製。

安永會計師事務所

執業會計師
香港
鰂魚涌
英皇道979號
太古坊一座27樓

2022年8月23日

Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income

中期簡明綜合損益及其他全面收益報表

For the six months ended 30 June 2022 截至2022年6月30日止六個月

		For the six months ended 30 June 截至6月30日止六個月	
		2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元	2021 2021年 (Unaudited) (未經審核) RMB'000 人民幣千元
	Notes 附註		
REVENUE	收益	4	2,850,489
Cost of sales	銷售成本		(2,326,223)
Gross profit	毛利		524,266
Other income	其他收入	5	94,842
Other gains and losses, net	其他收益及虧損淨額	6	(77,069)
Selling and distribution expenses	銷售及分銷費用		(8,779)
Administrative expenses	行政費用		(292,473)
Impairment losses/(reversal of impairment losses) on financial assets, net	金融資產減值虧損／ (減值虧損撥回)淨額		(770)
Other expenses	其他費用		(5,081)
Finance costs	財務費用		(11,970)
Share of profits and losses of:	應佔利潤及虧損：		
A joint venture	一間合營公司		(4,217)
Associates	聯營公司		35,426
PROFIT BEFORE TAX	稅前利潤	7	254,175
Income tax expense	所得稅費用	8	(39,428)
PROFIT AND TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	期內利潤和全面收入總額		214,747
Attributable to:	應佔：		
Owners of the parent	母公司擁有人		201,589
Non-controlling interests	非控股權益		13,158
			214,747
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	母公司普通股權益持有人應佔每股盈利	10	
Basic (RMB yuan)	基本(人民幣元)		0.16
Diluted (RMB yuan)	攤薄(人民幣元)		0.16

Interim Condensed Consolidated Statement of Financial Position

中期簡明綜合財務狀況報表

30 June 2022 2022年6月30日

			30 June 2022 2022年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2021 2021年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
	Notes 附註			
NON-CURRENT ASSETS		非流動資產		
Property, plant and equipment	11	物業、廠房及設備	1,905,407	1,754,607
Right-of-use assets		使用權資產	377,456	363,835
Goodwill	17	商譽	2,434,568	2,276,258
Other intangible assets	12	其他無形資產	72,004	75,351
Investment in a joint venture		於一間合營公司之投資	—	302,940
Investments in associates		於聯營公司之投資	997,136	961,710
Receivables from invest-operate-transfer ("IOT") hospitals		來自投資—營運—移交(IOT)醫院之應收款項	59,988	58,898
Financial assets at fair value through profit or loss ("FVTPL")		以公允價值計量且其變動計入損益(以「公允價值計量且其變動計入損益」)的金融資產	58,882	65,301
Other financial assets at amortised cost	13	其他按攤銷成本計量的金融資產	716,281	597,670
Deferred tax assets		遞延稅項資產	10,555	10,181
Other non-current assets		其他非流動資產	76,269	76,269
Total non-current assets		非流動資產總額	6,708,546	6,543,020
CURRENT ASSETS		流動資產		
Inventories		存貨	178,556	185,075
Trade and bills receivables	14	應收貿易款項及應收票據	1,011,547	766,603
Contract assets		合約資產	22,620	27,560
Prepayments, deposits and other receivables	15	預付款項、保證金及其他應收款項	294,447	298,529
Due from related parties	19	應收關聯方款項	7,164	7,141
Financial assets at FVTPL	13	以公允價值計量且其變動計入損益的金融資產	80,674	—
Other financial assets at amortised cost		其他按攤銷成本計量的金融資產	210,536	311,031
Restricted and pledged bank deposits		限制性和已抵押銀行存款	5,822	4,592
Cash and cash equivalents		現金及現金等價物	2,343,450	2,324,051
Total current assets		流動資產總額	4,154,816	3,924,582
CURRENT LIABILITIES		流動負債		
Trade and bills payables	16	應付貿易款項及應付票據	895,520	827,574
Other payables and accruals		其他應付款項及應計費用	752,955	757,989
Due to related parties	19	應付關聯方款項	140,262	126,283
Payables to hospitals sponsored by the Group (the "Sponsored Hospitals")		應付本集團舉辦之醫院(「舉辦權醫院」)款項	—	166
Interest-bearing bank and other borrowings		計息銀行及其他借款	802,305	1,665,899
Lease liabilities		租賃負債	38,446	22,225
Deferred income		遞延收入	2,428	817
Tax payable		應繳稅金	40,292	42,781
Total current liabilities		流動負債總額	2,672,208	3,443,734
NET CURRENT ASSETS		流動資產淨額	1,482,608	480,848
TOTAL ASSETS LESS CURRENT LIABILITIES		總資產減流動負債	8,191,154	7,023,868

Interim Condensed Consolidated Statement of Financial Position

中期簡明綜合財務狀況報表

30 June 2022 2022年6月30日

		30 June 2022 2022年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2021 2021年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
NON-CURRENT LIABILITIES	非流動負債		
Lease liabilities	租賃負債	45,973	40,250
Retirement benefit obligations	退休福利責任	49,275	37,478
Deferred tax liabilities	遞延稅項負債	70,216	95,251
Provision	撥備	1,826	327
Deferred income	遞延收入	15,016	4,117
Interest-bearing bank borrowings	計息銀行借款	940,710	—
Total non-current liabilities	非流動負債總額	1,123,016	177,423
Net assets	資產淨值	7,068,138	6,846,445
EQUITY	權益		
Equity attributable to owners of the parent	母公司擁有人應佔權益		
Share capital	股本	267	267
Reserves	儲備	6,524,700	6,450,509
		6,524,967	6,450,776
Non-controlling interests	非控股權益	543,171	395,669
Total equity	總權益	7,068,138	6,846,445

Cheng Libing

成立兵

Director

董事

Ren Yuan

任遠

Director

董事

Interim Condensed Consolidated Statement of Changes in Equity

中期簡明綜合權益變動報表

For the six months ended 30 June 2022 截至2022年6月30日止六個月

		Attributable to owners of the parent 母公司擁有人應佔											
		Share capital 股本	Share premium account 股份溢價賬	Capital reserve 資本公積	Statutory surplus reserve 法定盈餘公積	Treasury shares reserve 庫存股份儲備	Share-based payment reserve 股份付款儲備	Exchange fluctuation reserve 匯兌波動儲備	Actuarial changes reserve 精算變動儲備	Retained profits 保留利潤	Total 總計	Non-controlling interests 非控股權益	Total 總計
	Notes 附註	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元
At 1 January 2022	於2022年1月1日	267	5,785,472	(341,049)	198,219	(280,448)	30,432	567	(15,231)	1,072,547	6,450,776	395,669	6,846,445
Profit and total comprehensive income for the period	期內利潤及全面收入總額	-	-	-	-	-	-	-	-	201,589	201,589	13,158	214,747
Acquisition of subsidiaries	收購附屬公司	-	-	-	-	-	-	-	-	-	-	134,906	134,906
Disposal of a subsidiary	處置一間附屬公司	-	-	-	-	-	-	-	-	-	-	(44)	(44)
Equity-settled share-based payment arrangement	按權益結算以股份付款安排	-	-	-	-	-	2,204	-	-	-	2,204	25	2,229
Shares vested under the Share Award Scheme	根據股份獎勵計劃歸屬的股份	-	(33,210)	-	-	66,666	(33,456)	-	-	-	-	-	-
Final 2021 dividend	2021年末期股息	-	(129,602)	-	-	-	-	-	-	-	(129,602)	-	(129,602)
Dividend paid to non-controlling interests of subsidiaries of Company	支付予本公司附屬公司非控股權益之股息	-	-	-	-	-	-	-	-	-	-	(543)	(543)
At 30 June 2022 (unaudited)	於2022年6月30日 (未經審核)	267	5,622,660*	(341,049)*	198,219*	(213,782)*	(820)*	567*	(15,231)*	1,274,136**	6,524,967	543,171	7,068,138

* These reserve accounts comprise the consolidated reserves of RMB6,524,700,000 (31 December 2021: RMB6,450,509,000) in the interim condensed consolidated statement of financial position as at 30 June 2022. 該等儲備賬包包括於2022年6月30日中期簡明綜合財務狀況報表內人民幣6,524,700,000元(2021年12月31日:人民幣6,450,509,000元)的綜合儲備。

* Included in the balance as at 30 June 2022 was accumulated profits of the Group's consolidated not-for-profit hospitals of RMB116,549,000 (31 December 2021: RMB53,088,000). 於2022年6月30日該項餘額包括本集團併表非營利醫院之累計利潤人民幣116,549,000元(2021年12月31日:人民幣53,088,000元)。

Interim Condensed Consolidated Statement of Changes in Equity

中期簡明綜合權益變動報表

For the six months ended 30 June 2022 截至2022年6月30日止六個月

		Attributable to owners of the parent 母公司擁有人應佔											
		Share capital 股本	Share premium account 股份溢價賬	Capital reserve 資本公積	Statutory surplus reserve 法定盈餘公積	Treasury shares 庫存股份	Share-based payment reserve 股份付款儲備	Exchange fluctuation reserve 匯兌波動儲備	Actuarial changes reserve 精算變動儲備	Retained profits 保留利潤	Total 總計	Non-controlling interests 非控股權益	Total 總計
		RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元
At 1 January 2021	於2021年1月1日	267	5,877,796	(342,030)	188,432	(282,765)	20,663	567	(21,833)	664,419	6,105,456	234,998	6,340,454
Profit and total comprehensive income for the period	期內利潤及全面收入總額	—	—	—	—	—	—	—	—	199,315	199,315	6,010	205,325
Acquisition of subsidiaries	收購附屬公司	—	—	—	—	—	—	—	—	—	—	161,242	161,242
Acquisition of non-controlling interests	收購非控股權益	—	—	497	—	—	—	—	—	—	497	(1,519)	(1,022)
Equity-settled share-based payment arrangement	按權益結算以股份付款安排	—	—	—	—	—	5,660	—	—	—	5,660	5	5,665
Final 2020 dividend	2020年末期股息	—	(91,076)	—	—	—	—	—	—	—	(91,076)	—	(91,076)
At 30 June 2021 (unaudited)	於2021年6月30日 (未經審核)	267	5,786,720	(341,593)	188,432	(282,765)	26,323	567	(21,833)	863,734	6,219,852	400,736	6,620,588

Interim Condensed Consolidated Statement of Cash Flows

中期簡明綜合現金流量報表

For the six months ended 30 June 2022 截至2022年6月30日止六個月

		For the six months ended 30 June 截至6月30日止六個月	
		2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元	2021 2021年 (Unaudited) (未經審核) RMB'000 人民幣千元
	Notes 附註		
Net cash flows from operating activities	經營活動所得現金流量淨額	38,600	127,408
CASH FLOWS FROM INVESTING ACTIVITIES	投資活動所得現金流量		
Investment income on financial assets at FVTPL	以公允價值計量且其變動計入損益的金融資產投資收入	12,289	7,294
Dividend received from a financial asset at FVTPL	自以公允價值計量且其變動計入損益的金融資產收取之股息	3,249	2,795
Purchases of items of property, plant and equipment	購買物業、廠房及設備項目	(94,240)	(74,329)
Proceeds from disposal of items of property, plant and equipment	處置物業、廠房及設備項目所得款項	3,872	2,075
Receipt of government grant for property, plant and equipment	收到的與物業、廠房及設備相關的政府補助款項	—	4,085
Purchases of financial assets at FVTPL	購買以公允價值計量且其變動計入損益的金融資產	(1,957,100)	(1,565,000)
Proceeds from disposal of financial assets at FVTPL	處置以公允價值計量且其變動計入損益的金融資產所得款項	1,877,239	1,517,904
Purchases of other financial assets at amortised cost	購買其他按攤銷成本計量的金融資產	(180,000)	(420,000)
Proceeds from disposal of other financial assets at amortised cost	處置其他按攤銷成本計量的金融資產所得款項	179,935	16,936
Repayment from IOT hospitals	來自IOT醫院之還款	3,687	2,387
Investment in an associate	於一間聯營公司之投資	—	(869,117)
Acquisition of non-controlling interests	收購非控股權益	—	(1,022)
Disposal of a subsidiary	處置一間附屬公司	50	—
Acquisition of subsidiaries	收購附屬公司	173,918	(841,452)
Settlement of consideration for the acquisition of subsidiaries	收購附屬公司的對價結算	—	(17,306)
(Increase)/decrease in restricted and pledged bank deposits	限制性和已抵押銀行存款(增加)/減少	(1,230)	17,422
Net cash flows from/(used in) investing activities	投資活動所得/(所用)現金流量淨額	21,669	(2,217,328)

Interim Condensed Consolidated Statement of Cash Flows

中期簡明綜合現金流量報表

For the six months ended 30 June 2022 截至2022年6月30日止六個月

		For the six months ended 30 June 截至6月30日止六個月	
		2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元	2021 2021年 (Unaudited) (未經審核) RMB'000 人民幣千元
CASH FLOWS FROM FINANCING ACTIVITIES	融資活動所得現金流量		
Repayment of payables to the Sponsored Hospitals	向舉辦權醫院償還應付款項	—	(724)
New bank borrowings	新銀行借款	4,392,577	2,968,812
Repayment of bank borrowings	銀行借款的還款	(4,414,259)	(1,983,130)
Principal portion of lease payments	租賃付款的本金部分	(8,499)	(5,847)
Dividend paid	已付股息	—	(91,076)
Dividends paid to non-controlling shareholders	支付予非控股股東之股息	(543)	—
Interest paid	已付利息	(11,891)	(8,193)
Net cash flows from/(used in) financing activities	融資活動所得/(所用)現金流量淨額	(42,615)	879,842
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS	現金及現金等價物增加/(減少)淨額	17,654	(1,210,078)
Cash and cash equivalents at beginning of period	期初現金及現金等價物	2,324,051	2,701,370
Effect of foreign exchange rate changes, net	匯率變動影響淨額	1,745	(4,372)
CASH AND CASH EQUIVALENTS AT END OF PERIOD	期末現金及現金等價物	2,343,450	1,486,920

Notes to Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

30 June 2022 2022年6月30日

1. CORPORATE INFORMATION

China Resources Medical Holdings Company Limited is a limited liability company incorporated in the Cayman Islands. The address of the registered office of the Company is 4th Floor, Harbour Place, 103 South Church Street, PO Box 10240, Grand Cayman KY1-1002, Cayman Islands. The principal place of business of the Company in Mainland China is located at 14/F, Kunlun Centre Office Building No. 5, Courtyard No. 9, Fuyi Street, Fengtai District, Beijing, the People's Republic of China (the "PRC").

During the period, the Company and its subsidiaries (collectively referred to as the "Group") were mainly engaged in the provision of general healthcare services, hospital management services, group purchasing organisation ("GPO") business and other hospital-derived services in Mainland China.

1. 公司資料

華潤醫療控股有限公司於開曼群島註冊成立為有限責任公司。本公司註冊辦事處地址為4th Floor, Harbour Place, 103 South Church Street, PO Box 10240, Grand Cayman KY1-1002, Cayman Islands。本公司在中國內地的主要營業地點位於中華人民共和國（「中國」）北京市豐台區福宜街9號院5號昆侖中心寫字樓14樓。

報告期間，本公司及其附屬公司（統稱「本集團」）主要從事於中國內地提供綜合醫療服務、提供醫院管理服務、集團採購組織（「GPO」）業務以及其他醫院衍生服務。

Notes to Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

30 June 2022 2022年6月30日

2.1 BASIS OF PREPARATION

These interim condensed consolidated financial information of the Group for the six months ended 30 June 2022 has been prepared in accordance with International Accounting Standard (“IAS”) 34 *Interim Financial Reporting* issued by the International Accounting Standards Board.

These interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group’s annual consolidated financial statements for the year ended 31 December 2021.

These interim condensed consolidated financial information has been prepared under the historical cost convention, except for financial assets at FVTPL which have been measured at fair value. The financial information is presented in Renminbi (“RMB”) and all values are rounded to the nearest thousand, except when otherwise indicated.

2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group’s annual consolidated financial statements for the year ended 31 December 2021, except for the adoption of the following revised International Financial Reporting Standards (“IFRSs”) for the first time for the current period’s financial information.

Amendments to IFRS 3	<i>Reference to the Conceptual Framework</i>
Amendments to IAS 16	<i>Property, Plant and Equipment: Proceeds before Intended Use</i>
Amendment to IAS 37	<i>Onerous Contracts — Cost of Fulfilling a Contract</i>
<i>Annual Improvements to IFRSs 2018–2020</i>	Amendments to IFRS 1, IFRS 9, Illustrative Examples accompanying IFRS 16, and IAS 41

2.1 編製基準

本集團截至2022年6月30日止六個月的中期簡明綜合財務資料乃根據國際會計準則理事會頒佈的國際會計準則（「國際會計準則」）第34號*中期財務報告*編製。

中期簡明綜合財務資料並不包括年度財務報表所規定的所有資料及披露，並應與本集團截至2021年12月31日止年度的年度綜合財務報表一併閱讀。

中期簡明綜合財務資料已根據歷史成本慣例編製，惟以公允價值計量且其變動計入損益的金融資產按公允價值計量除外。該財務資料乃以人民幣（「人民幣」）呈列，且除另有說明者外，所有金額進位至最接近的千元人民幣。

2.2 會計政策變動及披露

編製中期簡明綜合財務資料所用的會計政策與編製本集團截至2021年12月31日止年度的年度綜合財務報表所依循者貫徹一致，惟就目前期間之財務資料首次採納之以下經修訂國際財務報告準則（「國際財務報告準則」）除外。

國際財務報告準則第3號之修訂	<i>提述概念框架</i>
國際會計準則第16號之修訂	<i>物業、廠房及設備：作擬定用途前的所得款項</i>
國際會計準則第37號之修訂	<i>繁苛合同 — 履行合同的成本</i>
<i>國際財務報告準則2018年至2020年的年度改進</i>	國際財務報告準則第1號、國際財務報告準則第9號、國際財務報告準則第16號隨附說明範例及國際會計準則第41號之修訂

2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (continued)

The nature and impact of the revised IFRSs are described below:

- (a) Amendments to IFRS 3 replace a reference to the previous Framework for the Preparation and Presentation of Financial Statements with a reference to the Conceptual Framework for Financial Reporting issued in June 2018 without significantly changing its requirements. The amendments also add to IFRS 3 an exception to its recognition principle for an entity to refer to the Conceptual Framework to determine what constitutes an asset or a liability. The exception specifies that, for liabilities and contingent liabilities that would be within the scope of IAS 37 or IFRIC 21 if they were incurred separately rather than assumed in a business combination, an entity applying IFRS 3 should refer to IAS 37 or IFRIC 21 respectively instead of the Conceptual Framework. Furthermore, the amendments clarify that contingent assets do not qualify for recognition at the acquisition date. The Group has applied the amendments prospectively to business combinations that occurred on or after 1 January 2022. As there were no contingent assets, liabilities and contingent liabilities within the scope of the amendments arising in the business combination that occurred during the period, the amendments did not have any impact on the financial position and performance of the Group.

2.2 會計政策變動及披露 (續)

經修訂國際財務報告準則之性質及其影響闡述如下：

- (a) 國際財務報告準則第3號之修訂以2018年6月刊發「財務報告概念框架」的提述，取代對先前的「財務報表編製及呈列框架」的提述，而不大幅更改其要求。有關修訂亦在國際財務報告準則第3號加入確認原則的例外情況，實體可參考概念框架以釐定資產或負債的構成要素。該例外情況訂明，對於單獨而非在業務合併中承擔且屬於國際會計準則第37號或國際財務報告詮釋委員會第21號範圍的負債及或有負債，應用國際財務報告準則第3號的實體應分別提述國際會計準則第37號或國際財務報告詮釋委員會第21號，而非概念框架。此外，有關修訂釐清，或有資產於收購日期不符合確認資格。本集團已按未來基準對2022年1月1日或之後發生的業務合併應用有關修訂。由於期內發生的業務合併並無產生修訂範圍內的或有資產、負債及或有負債，因此有關修訂對本集團的財務狀況及表現並無造成任何影響。

2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (continued)

(b) Amendments to IAS 16 prohibit an entity from deducting from the cost of an item of property, plant and equipment any proceeds from selling items produced while bringing that asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Instead, an entity recognises the proceeds from selling any such items, and the cost of those items, in profit or loss. The Group has applied the amendments retrospectively to items of property, plant and equipment made available for use on or after 1 January 2021. Since there was no sale of items produced while making property, plant and equipment available for use on or after 1 January 2021, the amendments did not have any impact on the financial position or performance of the Group.

(c) Amendments to IAS 37 clarify that for the purpose of assessing whether a contract is onerous under IAS 37, the cost of fulfilling the contract comprises the costs that relate directly to the contract. Costs that relate directly to a contract include both the incremental costs of fulfilling that contract (e.g., direct labour and materials) and an allocation of other costs that relate directly to fulfilling that contract (e.g., an allocation of the depreciation charge for an item of property, plant and equipment used in fulfilling the contract as well as contract management and supervision costs). General and administrative costs do not relate directly to a contract and are excluded unless they are explicitly chargeable to the counterparty under the contract. The Group has applied the amendments prospectively to contracts for which it has not yet fulfilled all its obligations at 1 January 2022 and no onerous contracts were identified. Therefore, the amendments did not have any impact on the financial position or performance of the Group.

2.2 會計政策變動及披露 (續)

(b) 國際會計準則第16號之修訂禁止實體從物業、廠房及設備項目成本中扣除資產達致所需地點和狀況(以使該資產能按管理層預定的方式運作)期間產生的任何項目銷售所得款項。取而代之，實體會在損益確認任何該等項目的銷售所得款項及該等項目的成本。本集團已對2021年1月1日或之後可供使用的物業、廠房及設備項目追溯應用有關修訂。由於2021年1月1日或之後並無銷售在令物業、廠房及設備可供使用期間所產生的項目，因此該等修訂並無對本集團的財務狀況或表現產生任何影響。

(c) 國際會計準則第37號之修訂釐清，就根據國際會計準則第37號評估某合同是否繁苛而言，履行合同成本包括直接與合同相關的成本。與合同直接相關的成本包括履行該合同的遞增成本(例如直接勞工和材料)及與履行該合同直接相關的其他成本分配(例如分配履行合同所用的物業、廠房及設備項目的折舊費用以及合同管理和監督成本)。一般及行政成本與合同並無直接關係，除非合同訂明可向對手方收取，否則將排除在外。本集團已按未來基準對其於2022年1月1日尚未履行全部義務的合同應用有關修訂，並未識別到任何繁苛合同。因此，該等修訂並無對本集團的財務狀況或表現產生任何影響。

2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (continued)

2.2 會計政策變動及披露 (續)

(d) *Annual Improvements to IFRSs 2018–2020* sets out amendments to IFRS 1, IFRS 9, Illustrative Examples accompanying IFRS 16, and IAS 41. Details of the amendments that are applicable to the Group are as follows:

- IFRS 9 *Financial Instruments*: clarifies the fees that an entity includes when assessing whether the terms of a new or modified financial liability are substantially different from the terms of the original financial liability. These fees include only those paid or received between the borrower and the lender, including fees paid or received by either the borrower or lender on the other's behalf. The Group has applied the amendment prospectively to financial liabilities that are modified or exchanged on or after 1 January 2022. As there was no modification of the Group's financial liabilities during the period, the amendment did not have any impact on the financial position or performance of the Group.
- IFRS 16 *Leases*: removes the illustration of payments from the lessor relating to leasehold improvements in Illustrative Example 13 accompanying IFRS 16. This removes potential confusion regarding the treatment of lease incentives when applying IFRS 16.

(d) 國際財務報告準則2018年至2020年的年度改進載列國際財務報告準則第1號、國際財務報告準則第9號、國際財務報告準則第16號隨附說明範例及國際會計準則第41號之修訂。適用於本集團的有關修訂詳情如下：

- 國際財務報告準則第9號「金融工具」：釐清在評估新訂或經修改金融負債的條款與原金融負債的條款存在重大差異時，實體所計入的費用。該等費用僅包括借款人與貸款人之間已支付或已收取的費用，包括借款人或貸款人代表對方支付或收取的費用。本集團已按未來基準對2022年1月1日或之後修改或交換的金融負債應用有關修訂。由於本集團的金融負債於期內並無任何修改，因此有關修訂對本集團的財務狀況或表現並無造成任何影響。
- 國際財務報告準則第16號「租賃」：刪除國際財務報告準則第16號隨附說明範例13中有關租賃資產改良的出租人付款說明，以免應用國際財務報告準則第16號時對租賃優惠的處理方式可能出現混淆。

Notes to Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

30 June 2022 2022年6月30日

3. OPERATING SEGMENT INFORMATION

For management purposes, the Group is organised into business units based on their services and has three reportable operating segments as follows:

- (a) Self-owned hospitals — this segment engages in the provision of out-patient and in-patient services by the consolidated hospitals and the provision of services to the unconsolidated hospitals;
- (b) IOT/operate-transfer (“OT”) hospitals — this segment engages in the provision of services to IOT hospitals and OT hospitals; and
- (c) Others — this segment engages in the provision of services to other kinds of clients.

Management monitors the results of the Group’s operating segments separately for the purpose of facilitating decision-making process of resource allocation and performance assessment. Segment performance is evaluated based on reportable segment profit/loss, which is a measurement of adjusted profit before tax. The adjusted profit before tax is measured consistently with the Group’s profit before tax except that fair value losses on financial assets at FVTPL, dividend income on a financial asset at FVTPL, gain on disposal of a subsidiary, investment income on financial assets at FVTPL, investment income on other financial assets at amortised cost, unallocated interest and investment income, unallocated impairment losses/ (reversal of impairment losses) on financial assets, net, equity-settled share-based payment expense, unallocated finance costs, foreign exchange differences, net, unallocated share of profits and losses of a joint venture and associates as well as other unallocated income, other unallocated administrative expenses, other unallocated expenses and losses are excluded from such measurement.

3. 經營分部資料

就管理目的，本集團乃根據服務組成業務單位，並有下列三個可報告經營分部：

- (a) 自有醫院 — 該分部由併表醫院從事提供門診及住院服務，以及向非併表醫院提供服務；
- (b) IOT／營運 — 移交（「OT」）醫院 — 該分部從事向IOT醫院及OT醫院提供服務；及
- (c) 其他 — 該分部從事向其他類別客戶提供服務。

管理層獨立監察本集團經營分部之業績，以便作出有關資源分配之決定及評估表現。分部表現乃根據可報告分部利潤／虧損（乃經調整稅前利潤之計量基準）評估。經調整稅前利潤乃與本集團稅前利潤貫徹計量，惟有關計量並不包括以公允價值計量且其變動計入損益的金融資產公允價值虧損、以公允價值計量且其變動計入損益的金融資產的股息收入、處置一間附屬公司收益、以公允價值計量且其變動計入損益的金融資產投資收入、其他按攤銷成本計量的金融資產投資收入、未分配利息及投資收入、未分配金融資產減值虧損／（減值虧損撥回）淨額、按權益結算以股份付款開支、未分配財務費用、匯兌差異淨額、未分配應佔一間合營公司及聯營公司利潤及虧損，以及其他未分配收入、其他未分配行政費用、其他未分配開支及虧損。

3. OPERATING SEGMENT INFORMATION

(continued)

Segment assets exclude goodwill, financial assets at FVTPL, other financial assets at amortised cost, restricted and pledged bank deposits, cash and cash equivalents and other unallocated head office and corporate assets as these assets are managed on a group basis.

Segment liabilities exclude interest-bearing bank borrowings and other unallocated head office and corporate liabilities as these liabilities are managed on a group basis.

Intersegment sales and transfers are transacted with reference to the selling prices used for sales made to third parties at the then prevailing market prices.

The following is an analysis of the Group's revenue and results, and assets and liabilities by reportable and operating segments.

3. 經營分部資料(續)

分部資產不包括商譽、以公允價值計量且其變動計入損益的金融資產、其他按攤銷成本計量的金融資產、限制性和已抵押銀行存款、現金及現金等價物、其他未分配總部及企業資產，原因為該等資產乃於集團層面管理。

分部負債不包括計息銀行借款及其他未分配總部及企業負債，原因為該等負債乃於集團層面管理。

分部間銷售及轉讓乃參考按當時現行市場價格向第三方作出銷售所用的售價進行交易。

以下是按可報告和經營分部對本集團的收益和業績以及資產和負債的分析。

Notes to Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

30 June 2022 2022年6月30日

3. OPERATING SEGMENT INFORMATION 3. 經營分部資料(續)

(continued)

Segment revenue and results

分部收益及業績

		Self-owned hospitals 自有醫院 (Unaudited) (未經審核) RMB'000 人民幣千元	IOT/OT hospitals IOT/OT醫院 (Unaudited) (未經審核) RMB'000 人民幣千元	Others 其他 (Unaudited) (未經審核) RMB'000 人民幣千元	Total 總計 (Unaudited) (未經審核) RMB'000 人民幣千元
Six months ended 30 June 2022	截至2022年6月30日止 六個月				
External revenue	外部收益				
General healthcare services	綜合醫療服務	2,322,778	—	—	2,322,778
Hospital management services	醫院管理服務	—	13,712	—	13,712
Third-party supply chain service fees	第三方供應鏈服務費	76,237	26,363	—	102,600
GPO business	GPO業務	220,025	184,061	—	404,086
Other hospital-derived services	其他醫院衍生服務	—	—	7,313	7,313
Inter-segment revenue	分部間收益				
Hospital management services	醫院管理服務	62,142	—	—	62,142
GPO business	GPO業務	162,938	—	—	162,938
Other hospital-derived services	其他醫院衍生服務	4,083	—	687	4,770
Segment revenue	分部收益	2,848,203	224,136	8,000	3,080,339
Eliminations	抵銷	(229,163)	—	(687)	(229,850)
Consolidated revenue	綜合收益	2,619,040	224,136	7,313	2,850,489
Segment cost	分部成本	(2,162,106)	(153,492)	(10,625)	(2,326,223)
Other income	其他收入	28,316	3,778	3,881	35,975
Other gains	其他收益	351	—	—	351
Selling and distribution expenses	銷售及分銷費用	(6,331)	(2,193)	(160)	(8,684)
Administrative expenses	行政費用	(237,078)	(13,386)	(5,740)	(256,204)
Finance costs	財務費用	(1,172)	—	(8)	(1,180)
Impairment losses on financial assets, net	金融資產減值虧損淨額	(2,555)	—	(384)	(2,939)
Other expenses	其他費用	(5,025)	—	(17)	(5,042)
Share of loss of a joint venture	應佔一間合營公司虧損	(4,217)	—	—	(4,217)
Share of profits of associates	應佔聯營公司利潤	35,426	—	—	35,426

Notes to Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

30 June 2022 2022年6月30日

3. OPERATING SEGMENT INFORMATION 3. 經營分部資料 (續)

(continued)

Segment revenue and results (continued)

分部收益及業績 (續)

		Self-owned hospitals 自有醫院 (Unaudited) (未經審核) RMB'000 人民幣千元	IOT/OT hospitals IOT/OT醫院 (Unaudited) (未經審核) RMB'000 人民幣千元	Others 其他 (Unaudited) (未經審核) RMB'000 人民幣千元	Total 總計 (Unaudited) (未經審核) RMB'000 人民幣千元
Segment results	分部業績	264,649	58,843	(5,740)	317,752
Fair value losses on financial assets at FVTPL	以公允價值計量且其變動計入損益的金融資產公允價值虧損				(419)
Dividend income on a financial asset at FVTPL	以公允價值計量且其變動計入損益的金融資產的股息收入				3,249
Gain on disposal of a subsidiary	處置一間附屬公司收益				89
Investment income on financial assets at FVTPL	以公允價值計量且其變動計入損益的金融資產投資收入				8,537
Investment income on other financial assets at amortised cost	其他按攤銷成本計量的金融資產投資收入				21,803
Unallocated interest and investment income	未分配利息及投資收入				8,813
Unallocated reversal of impairment losses on financial assets, net	未分配金融資產減值虧損撥回淨額				2,169
Equity-settled share-based payment expense	按權益結算以股份付款開支				(2,229)
Unallocated finance costs	未分配財務費用				(10,790)
Foreign exchange differences, net	匯兌差異淨額				(77,053)
Other unallocated income	其他未分配收入				16,465
Other unallocated losses	其他未分配虧損				(37)
Other unallocated administrative expenses	其他未分配行政費用				(34,135)
Other unallocated expenses	其他未分配開支				(39)
Profit before tax	稅前利潤				254,175

Notes to Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

30 June 2022 2022年6月30日

3. OPERATING SEGMENT INFORMATION 3. 經營分部資料(續)

(continued)

Segment revenue and results (continued)

分部收益及業績(續)

		Self-owned hospitals 自有醫院 (Unaudited) (未經審核) RMB'000 人民幣千元	IOT/OT hospitals IOT/OT醫院 (Unaudited) (未經審核) RMB'000 人民幣千元	Others 其他 (Unaudited) (未經審核) RMB'000 人民幣千元	Total 總計 (Unaudited) (未經審核) RMB'000 人民幣千元
Six months ended 30 June 2021	截至2021年6月30日止 六個月				
External revenue	外部收益				
General healthcare services	綜合醫療服務	1,138,886	—	—	1,138,886
Hospital management services	醫院管理服務	28,532	19,396	—	47,928
Third-party supply chain service fees	第三方供應鏈服務費	78,461	19,757	—	98,218
GPO business	GPO業務	321,295	153,106	—	474,401
Other hospital-derived services	其他醫院衍生服務	—	—	12,690	12,690
Inter-segment revenue	分部間收益				
Hospital management services	醫院管理服務	38,012	—	—	38,012
GPO business	GPO業務	120,347	—	—	120,347
Other hospital-derived services	其他醫院衍生服務	1,752	—	2,237	3,989
Segment revenue	分部收益	1,727,285	192,259	14,927	1,934,471
Eliminations	抵銷	(160,111)	—	(2,237)	(162,348)
Consolidated revenue	綜合收益	1,567,174	192,259	12,690	1,772,123
Segment cost	分部成本	(1,230,513)	(133,842)	(13,194)	(1,377,549)
Other income	其他收入	9,632	4,615	6,283	20,530
Selling and distribution expenses	銷售及分銷費用	(6,051)	(1,901)	—	(7,952)
Administrative expenses	行政費用	(112,883)	(11,760)	(2,863)	(127,506)
Finance costs	財務費用	(1,144)	—	(33)	(1,177)
Reversal of impairment losses on financial assets, net	金融資產減值虧損撥回 淨額	1,012	—	—	1,012
Other expenses	其他費用	(1,008)	—	(131)	(1,139)
Share of profit of a joint venture	應佔一間合營公司利潤	630	—	—	630
Share of profits of associates	應佔聯營公司利潤	42,504	—	—	42,504

Notes to Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

30 June 2022 2022年6月30日

3. OPERATING SEGMENT INFORMATION 3. 經營分部資料 (續)

(continued)

Segment revenue and results (continued)

分部收益及業績 (續)

		Self-owned hospitals 自有醫院 (Unaudited) (未經審核) RMB'000 人民幣千元	IOT/OT hospitals IOT/OT醫院 (Unaudited) (未經審核) RMB'000 人民幣千元	Others 其他 (Unaudited) (未經審核) RMB'000 人民幣千元	Total 總計 (Unaudited) (未經審核) RMB'000 人民幣千元
Segment results	分部業績	269,353	49,371	2,752	321,476
Fair value losses on financial assets at FVTPL	以公允價值計量且其變動計入損益的金融資產公允價值虧損				(21,876)
Dividend income on a financial asset at FVTPL	以公允價值計量且其變動計入損益的金融資產的股息收入				2,795
Investment income on financial assets at FVTPL	以公允價值計量且其變動計入損益的金融資產投資收入				7,294
Investment income on other financial assets at amortised cost	其他按攤銷成本計量的金融資產投資收入				7,394
Unallocated interest and investment income	未分配利息及投資收入				15,744
Unallocated impairment losses on financial assets, net	未分配金融資產減值虧損淨額				(216)
Equity-settled share-based payment expense	按權益結算以股份付款開支				(5,104)
Unallocated finance costs	未分配財務費用				(4,701)
Foreign exchange differences, net	匯兌差異淨額				2,100
Unallocated share of profit of an associate	未分配應佔一間聯營公司利潤				580
Other unallocated income	其他未分配收入				940
Other unallocated administrative expenses	其他未分配行政費用				(56,275)
Other unallocated expenses	其他未分配開支				(9)
Profit before tax	稅前利潤				270,142

Notes to Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

30 June 2022 2022年6月30日

3. OPERATING SEGMENT INFORMATION 3. 經營分部資料 (續)

(continued)

Segment assets and liabilities

分部資產及負債

		Self-owned hospitals 自有醫院 (Unaudited) (未經審核) RMB'000 人民幣千元	IOT/OT hospitals IOT/OT醫院 (Unaudited) (未經審核) RMB'000 人民幣千元	Others 其他 (Unaudited) (未經審核) RMB'000 人民幣千元	Total 總計 (Unaudited) (未經審核) RMB'000 人民幣千元
As at 30 June 2022	於2022年6月30日				
Segment assets	分部資產	4,681,439	247,787	69,985	4,999,211
Goodwill	商譽				2,434,568
Financial assets at FVTPL	以公允價值計量且其變動計入損益的金融資產				139,556
Other financial assets at amortised cost	其他按攤銷成本計量的金融資產				926,817
Restricted and pledged bank deposits	限制性和已抵押銀行存款				5,822
Cash and cash equivalents	現金及現金等價物				2,343,450
Corporate and other unallocated assets	企業及其他未分配資產				1,293,805
Elimination of inter-segment receivables	分部間應收款項抵銷				(1,279,867)
Total assets	總資產				10,863,362
Segment liabilities	分部負債	2,170,558	25,610	60,424	2,256,592
Interest-bearing bank borrowings	計息銀行借款				1,743,015
Corporate and other unallocated liabilities	企業及其他未分配負債				1,082,313
Elimination of inter-segment payables	分部間應付款項抵銷				(1,286,696)
Total liabilities	總負債				3,795,224

Notes to Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

30 June 2022 2022年6月30日

3. OPERATING SEGMENT INFORMATION 3. 經營分部資料 (續)

(continued)

Segment assets and liabilities (continued)

分部資產及負債 (續)

		Self-owned	IOT/OT hospitals	Others	Total
		hospitals	hospitals		
		自有醫院	IOT/OT醫院	其他	總計
		RMB'000	RMB'000	RMB'000	RMB'000
		人民幣千元	人民幣千元	人民幣千元	人民幣千元
As at 31 December 2021	於2021年12月31日				
Segment assets	分部資產	3,146,178	256,595	75,389	3,478,162
Goodwill	商譽				2,276,258
Financial assets at FVTPL	以公允價值計量且其變動計入損益的金融資產				65,301
Other financial assets at amortised cost	其他按攤銷成本計量的金融資產				908,701
Restricted and pledged bank deposits	限制性和已抵押銀行存款				4,592
Cash and cash equivalents	現金及現金等價物				2,324,051
Corporate and other unallocated assets	企業及其他未分配資產				2,224,915
Elimination of inter-segment receivables	分部間應收款項抵銷				(814,378)
Total assets	總資產				10,467,602
Segment liabilities	分部負債	1,651,377	23,589	62,804	1,737,770
Interest-bearing bank borrowings	計息銀行借款				1,646,624
Corporate and other unallocated liabilities	企業及其他未分配負債				1,051,141
Elimination of inter-segment payables	分部間應付款項抵銷				(814,378)
Total liabilities	總負債				3,621,157

Notes to Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

30 June 2022 2022年6月30日

4. REVENUE

Disaggregated revenue information

For the six months ended 30 June 2022

4. 收益

收益資料明細

截至2022年6月30日止六個月

		General healthcare services 綜合醫療服務 (Unaudited) (未經審核) RMB'000 人民幣千元	Hospital management services 醫院管理服務 (Unaudited) (未經審核) RMB'000 人民幣千元	GPO business GPO業務 (Unaudited) (未經審核) RMB'000 人民幣千元	Other hospital-derived services 其他醫院 衍生服務 (Unaudited) (未經審核) RMB'000 人民幣千元	Elimination 抵銷 (Unaudited) (未經審核) RMB'000 人民幣千元	Total 總計 (Unaudited) (未經審核) RMB'000 人民幣千元
Type of goods or services	商品或服務類別						
General healthcare services	綜合醫療服務						
In-patient	住院服務	1,322,018	—	—	—	—	1,322,018
Out-patient	門診服務	1,000,760	—	—	—	—	1,000,760
		2,322,778	—	—	—	—	2,322,778
Hospital management services	醫院管理服務						
From self-owned hospitals	來自自有醫院	—	62,142	—	—	(62,142)	—
From IOT hospitals	來自IOT醫院	—	10,097	—	—	—	10,097
From OT hospitals	來自OT醫院	—	3,615	—	—	—	3,615
From third party suppliers (note)	來自第三方供應商(附註)	—	102,600	—	—	—	102,600
		—	178,454	—	—	(62,142)	116,312
GPO business	GPO業務						
From self-owned hospitals	來自自有醫院	—	—	382,963	—	(162,938)	220,025
From IOT hospitals	來自IOT醫院	—	—	184,061	—	—	184,061
		—	—	567,024	—	(162,938)	404,086
Other hospital-derived services	其他醫院衍生服務						
		—	—	—	12,083	(4,770)	7,313
Total	合計	2,322,778	178,454	567,024	12,083	(229,850)	2,850,489
Timing of revenue recognition	確認收益的時間						
A point in time	於某個時間點	1,000,760	—	567,024	12,083	(167,708)	1,412,159
Over time	於一段時間內	1,322,018	178,454	—	—	(62,142)	1,438,330
Total	合計	2,322,778	178,454	567,024	12,083	(229,850)	2,850,489

Notes to Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

30 June 2022 2022年6月30日

4. REVENUE (continued)

Disaggregated revenue information

(continued)

For the six months ended 30 June 2021

4. 收益 (續)

收益資料明細 (續)

截至2021年6月30日止六個月

		General healthcare services 綜合醫療服務 (Unaudited) (未經審核) RMB'000 人民幣千元	Hospital management services 醫院管理服務 (Unaudited) (未經審核) RMB'000 人民幣千元	GPO business GPO業務 (Unaudited) (未經審核) RMB'000 人民幣千元	Other hospital-derived services 其他醫院 衍生服務 (Unaudited) (未經審核) RMB'000 人民幣千元	Elimination 抵銷 (Unaudited) (未經審核) RMB'000 人民幣千元	Total 總計 (Unaudited) (未經審核) RMB'000 人民幣千元
Type of goods or services	商品或服務類別						
General healthcare services	綜合醫療服務						
In-patient	住院服務	528,957	—	—	—	—	528,957
Out-patient	門診服務	609,929	—	—	—	—	609,929
		1,138,886	—	—	—	—	1,138,886
Hospital management services	醫院管理服務						
From self-owned hospitals	來自自有醫院	—	66,544	—	—	(38,012)	28,532
From IOT hospitals	來自IOT醫院	—	8,394	—	—	—	8,394
From OT hospitals	來自OT醫院	—	11,002	—	—	—	11,002
From third party suppliers (note)	來自第三方供應商(附註)	—	98,218	—	—	—	98,218
		—	184,158	—	—	(38,012)	146,146
GPO business	GPO業務						
From self-owned hospitals	來自自有醫院	—	—	441,642	—	(120,347)	321,295
From IOT hospitals	來自IOT醫院	—	—	153,106	—	—	153,106
		—	—	594,748	—	(120,347)	474,401
Other hospital-derived services	其他醫院衍生服務						
		—	—	—	16,679	(3,989)	12,690
Total	合計	1,138,886	184,158	594,748	16,679	(162,348)	1,772,123
Timing of revenue recognition	確認收益的時間						
A point in time	於某個時間點	609,929	—	594,748	16,679	(124,336)	1,097,020
Over time	於一段時間內	528,957	184,158	—	—	(38,012)	675,103
Total	合計	1,138,886	184,158	594,748	16,679	(162,348)	1,772,123

All of the Group's revenue is derived from the PRC.

本集團的所有收益均源於中國。

Notes to Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

30 June 2022 2022年6月30日

4. REVENUE (continued)

Disaggregated revenue information

(continued)

Note:

The Group entered into agreements with its third party suppliers for the joint development of a regional integrated pharmaceutical and/or medical consumable supply chain management system (the "Supply Chain Joint Development Agreements"). The Group provides supply chain management services to suppliers and recognises relevant revenue based on pre-set formulas set out in the Supply Chain Joint Development Agreements.

5. OTHER INCOME

4. 收益 (續)

收益資料明細 (續)

附註：

本集團與其第三方供應商簽訂區域藥品及/或醫用耗材供應鏈一體化管理體系合作共建協議(「供應鏈共建協議」)。本集團為供應商提供供應鏈管理服務，並按照供應鏈共建協議所載的預定公式確認相關收益。

5. 其他收入

		For the six months ended 30 June	
		截至6月30日止六個月	
		2022	2021
		2022年	2021年
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
		RMB'000	RMB'000
		人民幣千元	人民幣千元
Interest and investment income on:	利息及投資收入：		
Financial assets at FVTPL	以公允價值計量且其變動計入損益的金融資產	8,537	7,294
Other financial assets at amortised cost	其他按攤銷成本計量的金融資產	21,803	7,394
Receivables from IOT hospitals	來自IOT醫院之應收款項	3,778	4,615
Bank deposits	銀行存款	8,813	14,573
Loan to a sponsored hospital	向一間舉辦權醫院提供的貸款	—	1,171
Dividend income on a financial asset at FVTPL	以公允價值計量且其變動計入損益的金融資產的股息收入	3,249	2,795
Government grants	政府補助	4,493	9,605
Compensation received	收到賠償	14,725	—
Others	其他	29,444	7,250
		94,842	54,697

Notes to Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

30 June 2022 2022年6月30日

6. OTHER GAINS AND LOSSES, NET

6. 其他收益及虧損淨額

		For the six months ended 30 June 截至6月30日止六個月	
		2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元	2021 2021年 (Unaudited) (未經審核) RMB'000 人民幣千元
Fair value losses on financial assets at FVTPL	以公允價值計量且其變動計入損益的金融資產公允價值虧損	(281)	(21,876)
Foreign exchange differences, net	匯兌差異淨額	(77,053)	2,100
Gain on disposal of items of property, plant and equipment, net	處置物業、廠房及設備項目之收益淨額	176	—
Gain on disposal of a subsidiary	處置一間附屬公司收益	89	—
		(77,069)	(19,776)

Notes to Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

30 June 2022 2022年6月30日

7. PROFIT BEFORE TAX

The Group's profit before tax is arrived at after charging/(crediting):

7. 稅前利潤

本集團的稅前利潤乃經扣除/(計入)以下各項得出：

		For the six months ended 30 June 截至6月30日止六個月	
		2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元	2021 2021年 (Unaudited) (未經審核) RMB'000 人民幣千元
Cost of inventories sold	已售存貨成本	1,476,492	924,993
Depreciation of property, plant and equipment	物業、廠房及設備折舊	145,735	54,546
Depreciation of right-of-use assets	使用權資產折舊	22,828	9,907
Amortisation of intangible assets (included in cost of sales)	無形資產攤銷(計入銷售成本)	3,347	3,838
Total depreciation and amortisation	折舊及攤銷總額	171,910	68,291
Impairment/(reversal of impairment) of trade receivables, net	應收貿易款項減值/(減值撥回)淨額	1,233	(803)
Loss on disposal of items of property, plant and equipment, net	處置物業、廠房及設備項目虧損淨額	3,204	179

Notes to Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

30 June 2022 2022年6月30日

8. INCOME TAX

The PRC enterprise income tax has been provided at the rate of 25% (six months ended 30 June 2021: 25%) on the estimated assessable income arising in the PRC during the period. No provision for Hong Kong profits tax has been made as the Group did not generate any assessable profits arising in Hong Kong during the period (six months ended 30 June 2021: Nil).

8. 所得稅

期內，在中國產生估計應課稅收入者，均須按稅率25%（截至2021年6月30日止六個月：25%）計提中國企業所得稅撥備。由於本集團於本期內並無在香港產生任何應課稅利潤，因此並無計提香港利得稅撥備（截至2021年6月30日止六個月：無）。

		For the six months ended 30 June 截至6月30日止六個月	
		2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元	2021 2021年 (Unaudited) (未經審核) RMB'000 人民幣千元
Current — Mainland China	即期 — 中國內地	64,837	65,061
Deferred	遞延	(25,409)	(244)
Total tax charge for the period		39,428	64,817

Notes to Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

30 June 2022 2022年6月30日

9. DIVIDEND

9. 股息

		For the six months ended 30 June 截至6月30日止六個月	
		2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元	2021 2021年 (Unaudited) (未經審核) RMB'000 人民幣千元
Dividend recognised as distribution during the period:	於期內確認為分派之股息：		
Final 2021 — HK12.00 cents (2020: HK8.82 cents) per ordinary share	2021年末期 — 每股普通股12.00港仙 (2020年：8.82港仙)	133,042	94,054
Less: Dividend for shares held under the Share Award Scheme	減：根據股份獎勵計劃 持有股份的股息	(3,440)	(2,978)
		129,602	91,076

The Directors do not recommend the payment of an interim dividend for the six months ended 30 June 2022 (six months ended 30 June 2021: Nil).

董事並不建議就截至2022年6月30日止六個月派付中期股息(截至2021年6月30日止六個月：無)。

10. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculations of the basic and diluted earnings per share are based on:

10. 母公司普通股權益持有人應 佔每股盈利

每股基本及攤薄盈利乃根據以下數據計算得出：

		For the six months ended 30 June 截至6月30日止六個月	
		2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元	2021 2021年 (Unaudited) (未經審核) RMB'000 人民幣千元
Earnings	盈利		
Profit for the period attributable to ordinary equity holders of the parent for the purpose of the basic and diluted earnings per share calculation	用作計算每股基本及攤薄盈利之母公司普通股權益持有人應佔期內利潤	201,589	199,315

Notes to Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

30 June 2022 2022年6月30日

10. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

(continued)

10. 母公司普通股權益持有人應 佔每股盈利(續)

		For the six months ended 30 June 截至6月30日止六個月	
		2022 2022年 (Unaudited) (未經審核) '000 千股	2021 2021年 (Unaudited) (未經審核) '000 千股
Shares	股份		
Weighted average number of ordinary shares in issue during the period for the purpose of the basic earnings per share calculation	用作計算每股基本盈利之期內已發行加權平均普通股數目	1,257,753	1,255,952
Effect of dilution — weighted average number of ordinary shares:	加權平均普通股數目攤薄影響：		
Shares awarded under the Share Award Scheme	根據股份獎勵計劃授出之股份	900	7,117
Weighted average number of ordinary shares in issue during the period for the purpose of the diluted earnings per share calculation	用作計算每股攤薄盈利之期內已發行加權平均普通股數目	1,258,653	1,263,069

The weighted average number of shares used for the purpose of calculating the basic and diluted earnings per share for six months ended 30 June 2022 and 2021 has been arrived at after adjusting the effect of shares repurchased and held under the Share Award Scheme.

用於計算截至2022年及2021年6月30日止六個月每股基本及攤薄盈利之加權平均股份數目，乃經調整根據股份獎勵計劃購回及持有股份之影響後計算得出。

11. PROPERTY, PLANT AND EQUIPMENT

During the six months ended 30 June 2022, the Group acquired property, plant and equipment with an aggregate cost of RMB95,622,000 (six months ended 30 June 2021: RMB79,689,000), excluding property, plant and equipment acquired through business combinations disclosed in note 17 to the interim condensed consolidated financial information.

12. OTHER INTANGIBLE ASSETS

Other intangible assets of the Group represent operating rights under IOT arrangement and Good Supply Practice licence for pharmaceuticals.

13. FINANCIAL ASSETS AT FVTPL**11. 物業、廠房及設備**

截至2022年6月30日止六個月，本集團收購物業、廠房及設備的總成本為人民幣95,622,000元（截至2021年6月30日止六個月：人民幣79,689,000元），不包括通過中期簡明綜合財務資料附註17中披露的業務合併而獲得的物業、廠房及設備。

12. 其他無形資產

本集團的其他無形資產指IOT安排下之經營權以及藥品經營許可證。

13. 以公允價值計量且其變動計入損益的金融資產

		30 June 2022 2022年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2021 2021年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Listed equity investment, at fair value (note i)	上市股本投資，按公允價值（附註i）	58,882	65,301
Unlisted investments, at fair value (note ii)	非上市投資，按公允價值（附註ii）	80,674	—
		139,556	65,301
Analysed into:	分析為：		
Current portion	流動部分	80,674	—
Non-current portion	非流動部分	58,882	65,301
		139,556	65,301

Notes to Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

30 June 2022 2022年6月30日

13. FINANCIAL ASSETS AT FVTPL (continued)

Notes :

- (i) The listed equity investment was classified as financial assets at FVTPL as the Group has not elected to recognise the fair value gain or loss through other comprehensive income. It was held for long-term strategic purposes. The Group does not intend to dispose of it within twelve months after the end of the reporting periods.
- (ii) The unlisted investments were wealth management products issued by banks in Mainland China with expected return ranging from 2.3% to 3.3% per annum. The unlisted investments were mandatorily classified as financial assets at FVTPL as their contractual cash flows are not solely payments of principal and interest.

13. 以公允價值計量且其變動計入損益的金融資產(續)

附註：

- (i) 由於本集團選擇不透過其他全面收入確認公允價值收益或虧損，故上市股本投資分類為以公允價值計量且其變動計入損益的金融資產，乃持有作長期戰略用途。本集團無意於報告期末後十二個月內處置。
- (ii) 非上市投資是中國內地銀行發行的財富管理產品，預期每年回報介乎2.3%至3.3%。由於非上市投資的合同現金流量不僅是本金和利息的支付，因此被強制分類為以公允價值計量且其變動計入損益的金融資產。

14. TRADE AND BILLS RECEIVABLES

14. 應收貿易款項及應收票據

		30 June 2022 2022年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2021 2021年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Trade and bills receivables	應收貿易款項及應收票據		
Public health insurance programs and social organisation for medical services	公共醫療保險計劃及醫療服務社會組織	878,844	510,076
Other customers	其他客戶	220,757	339,717
Bills receivables	應收票據	1,684	370
		1,101,285	850,163
Impairment	減值	(89,738)	(83,560)
		1,011,547	766,603

14. TRADE AND BILLS RECEIVABLES

(continued)

The Group's trading terms with its customers are mainly on credit, except for new customers, where payment in advance is normally required. The credit periods range from 30 to 180 days. The Group seeks to maintain strict control over its outstanding receivables and has a credit control department to minimise credit risk. Overdue balances are reviewed regularly by senior management. The Group does not hold any collateral or other credit enhancements over its trade and bills receivable balances. Trade and bills receivables are non-interest-bearing.

An ageing analysis of the trade and bills receivables as at the end of the reporting periods, based on the invoice date and net of loss allowance, is as follows:

14. 應收貿易款項及應收票據 (續)

本集團與客戶的交易條款主要以信貸為基礎，但新客戶除外，新客戶通常需要預先付款。信用期為30天至180天不等。本集團致力就未收取的應收款項維持嚴格監控，並設有信貸控制部門，以降低信貸風險。高級管理層定期審閱逾期結餘。本集團並無就應收貿易款項及應收票據結餘持有任何抵押品或採取其他信貸增強措施。應收貿易款項及應收票據為免息。

於報告期末，應收貿易款項及應收票據的賬齡分析（根據發票日期及扣除虧損撥備）如下：

		30 June 2022 2022年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2021 2021年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Within 1 year	1年內	890,554	673,611
1 to 2 years	1年到2年	75,327	45,678
2 to 3 years	2年到3年	45,666	47,314
		1,011,547	766,603

Notes to Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

30 June 2022 2022年6月30日

15. PREPAYMENTS, DEPOSITS AND OTHER RECEIVABLES

15. 預付款項、保證金及其他應收款項

		30 June 2022 2022年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2021 2021年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Prepayments to suppliers	向供應商支付的預付款	18,118	30,456
Other receivable from "Yan Hua Hospital" (note (i))	來自「燕化醫院」的其他應收款項(附註(i))	189,747	189,747
Current portion of receivables from IOT hospital	來自IOT醫院之應收款項的即期部分	10,079	10,079
Others	其他	114,959	106,216
		332,903	336,498
Impairment	減值	(38,456)	(37,969)
		294,447	298,529

Note:

- (i) As disclosed in the announcements of the Company dated 15 January 2019, 21 January 2019 and 17 April 2019, Beijing Yan Hua Phoenix Healthcare Asset Management Company Limited (北京燕化鳳凰醫療資產管理有限公司) ("Yan Hua Phoenix"), the sponsor of Yan Hua Hospital, and Yan Hua Hospital unilaterally terminated the IOT agreement entered into between the Group, Yan Hua Phoenix and Yan Hua Hospital (the "Yan Hua IOT Agreement") from 21 January 2019. The Group has submitted a civil claim statement against Yan Hua Phoenix and Yan Hua Hospital in relation to the Yan Hua IOT Agreement dispute to the Beijing Second Intermediate People's Court on 17 April 2019 to seek the court's ruling that the unilateral termination of the Yan Hua IOT Agreement by Yan Hua Phoenix and Yan Hua Hospital on 21 January 2019 shall be void.

Having considered the terms of the Yan Hua IOT Agreement, the Group has further claimed that Yan Hua Phoenix and Yan Hua Hospital should be liable for damages for breach of the Yan Hua IOT Agreement. Accordingly, the Group reclassified the related receivables and operating right under the IOT arrangement with Yan Hua Hospital to other receivables during the year ended 31 December 2019.

註：

- (i) 誠如本公司日期為2019年1月15日、2019年1月21日及2019年4月17日的公告所披露，燕化醫院的舉辦人北京燕化鳳凰醫療資產管理有限公司(「燕化鳳凰」)和燕化醫院於2019年1月21日起單方面終止由本集團、燕化鳳凰及燕化醫院訂立的IOT協議(「燕化IOT協議」)。本集團已於2019年4月17日就燕化IOT協議爭議向北京市第二中級人民法院遞交民事起訴狀起訴燕化鳳凰及燕化醫院，要求法院判定燕化鳳凰及燕化醫院2019年1月21日單方面終止燕化IOT協議無效。

考慮到燕化IOT協議的條款，本集團進一步要求燕化鳳凰及燕化醫院須支付違反燕化IOT協議之違約金。據此，截至2019年12月31日止年度，本集團將對燕化醫院IOT安排下的相關應收款項和經營權重新分類到其他應收款項。

Notes to Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

30 June 2022 2022年6月30日

15. PREPAYMENTS, DEPOSITS AND OTHER RECEIVABLES (continued)

Note: (continued)

(i) (continued)

On 18 December 2019, the Beijing Second Intermediate People's Court issued a judgment in favour of the Group. Yan Hua Phoenix and Yan Hua Hospital filed an appeal to the Beijing Higher People's Court in January 2020. On 22 November 2021, the Beijing Higher People's Court handed down a judgment which rejected the appeal filed by Yan Hua Phoenix and Yan Hua Hospital and upheld the original judgment, and adjudged that such ruling shall be final.

16. TRADE AND BILLS PAYABLES

An ageing analysis of the trade and bills payables as at the end of the reporting periods, based on the date of delivery of goods, is as follows:

		30 June 2022 2022年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2021 2021年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Within 60 days	60天內	416,303	561,418
61 to 180 days	61天至180天	302,907	209,643
Over 180 days	180天以上	176,310	56,513
		895,520	827,574

The trade payables are non-interest-bearing and are normally granted a credit term of 0 to 90 days.

15. 預付款項、保證金及其他應收款項(續)

註：(續)

(i) (續)

於2019年12月18日，北京市第二中級人民法院宣佈有關起訴結果，本集團勝訴。燕化鳳凰和燕化醫院已於2020年1月向北京市高級人民法院提起上訴。於2021年11月22日，北京市高級人民法院頒佈判決，駁回燕化鳳凰和燕化醫院提起的上訴，維持原判決，並裁定此判決為終審判決。

16. 應付貿易款項及應付票據

於報告期末，應付貿易款項及應付票據賬齡分析乃基於交付商品日期作出如下：

應付貿易款項為免息，一般按0至90天的信貸期授出。

Notes to Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

30 June 2022 2022年6月30日

17. BUSINESS COMBINATION

On 30 January 2022, the Group entered into certain operational agreement (“Agreement”) of China Resource Wugang (Hubei) Hospital Management Co., Ltd. (“CR Wugang”) with Wugang Group Co., Ltd., an independent third party and shareholder of CR Wugang. The principal activities of CR Wugang and its sponsored hospitals (collectively referred to as “CR Wugang Group”), namely Wugang Hospital and Wuhan Iron and Steel (Group) Corporation No. 2 Staff Hospital, are engaged in hospital operation.

By virtue of the Agreement, the Group is exposed or has rights to variable returns from its involvement in CR Wugang Group and has ability to affect those returns through its power over CR Wugang Group (including existing rights that give the Group the practical ability to direct the relevant activities). Accordingly, the assets and liabilities of CR Wugang Group were consolidated in the Group’s financial statements thereafter.

Prior to the business combination, the Group held 51% equity interest of CR Wugang Group and accounted for its equity interest of CR Wugang as investment in a joint venture. Accordingly, the fair value of the investment in the joint venture of RMB298,723,000 as at 30 January 2022 formed the consideration for the business combination. Goodwill recognised on this business combination amounted to be RMB158,310,000.

The Group has elected to measure the non-controlling interests in CR Wugang Group at the non-controlling interests’ proportionate share of the CR Wugang Group’s identifiable net assets.

17. 業務合併

於2022年1月30日，本集團與武鋼集團有限公司（為獨立第三方及華潤武鋼（湖北）醫院管理有限公司（「華潤武鋼」）的股東）訂立了華潤武鋼的若干營運協議（「該協議」）。華潤武鋼及其舉辦權醫院（即武鋼醫院和武漢鋼鐵（集團）公司第二職工醫院）（統稱「華潤武鋼集團」）主要從事醫院營運。

憑藉該協議，本集團透過參與華潤武鋼集團而承擔或享有可變回報的風險或權利，並能夠透過其對華潤武鋼集團的權力（包括使本集團有實際能力指揮相關活動的現有權利）影響該等回報。因此，華潤武鋼集團的資產及負債其後合併至本集團的財務報表。

於此項業務合併前，本集團持有華潤武鋼集團的51%股權，而其於華潤武鋼的股權入賬為於合營公司之投資。因此，於2022年1月30日，於該合營公司之投資之公允價值人民幣298,723,000元構成了此項業務合併的對價。因該項業務合併而確認的商譽為人民幣158,310,000元。

本集團選擇按照非控股權益於華潤武鋼集團可識別淨資產的比例份額，計量華潤武鋼集團的非控股權益。

17. BUSINESS COMBINATION (continued)

The fair values of the considerations transferred, the identifiable net assets and the carrying amount of goodwill as at the date of business combination, which are provisional amounts, and are subject to the finalisation of the initial accounting for the business combination, were as follows:

17. 業務合併(續)

以下為於業務合併日期的已轉讓對價、可識別淨資產及商譽賬面值的公允價值，乃按暫定基準釐定，並視業務合併初始入賬完成而最終確定：

		Provisional fair value recognised on acquisition 因收購而確認的暫定公允價值 (Unaudited) (未經審核) RMB'000 人民幣千元
Property, plant and equipment	物業、廠房及設備	204,785
Right-of-use assets	使用權資產	36,557
Inventories	存貨	45,298
Trade and bills receivables	應收貿易款項及應收票據	218,045
Prepayments, deposits and other receivables	預付款項、保證金及 其他應收款項	36,816
Cash and cash equivalents	現金及現金等價物	173,918
Trade and bills payables	應付貿易款項及應付票據	(280,019)
Other payables and accruals	其他應付款項及應計費用	(80,626)
Interest-bearing borrowings	計息借款	(20,000)
Lease liabilities	租賃負債	(30,727)
Retirement benefit obligations	退休福利責任	(14,853)
Deferred income	遞延收入	(13,875)
Total identifiable net assets at provisional fair value	按暫定公允價值計量之 可識別淨資產的總額	275,319
Non-controlling interests	非控股權益	(134,906)
Goodwill on acquisition	收購商譽	158,310
		298,723
Satisfied by:	支付方式：	
Fair value of investment in a joint venture	於一間合營公司之投資 之公允價值	298,723

Notes to Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

30 June 2022 2022年6月30日

17. BUSINESS COMBINATION (continued)

Goodwill arose in the business combination of CR Wugang Group because the consideration paid for the business combination effectively included, inter alia, amounts in relation to the benefits of expected synergies from combining the respective operations of CR Wugang Group. These benefits are not recognised separately from goodwill because they do not meet the recognition criteria for identifiable intangible assets. None of the goodwill recognised is expected to be deductible for income tax purposes.

An analysis of the cash flows in respect of this business combination is as follows:

	RMB'000 人民幣千元 (Unaudited) (未經審核)
Cash and bank balances acquired and net inflow of cash and cash equivalents included in cash flows from investing activities	173,918

The fair values of the trade receivables and other receivables as at the date of the business combination amounted to RMB218,045,000 and RMB31,127,000, respectively. The gross contractual amounts of trade receivables and other receivables were RMB267,495,000 and RMB32,248,000, respectively.

Since the business combination, CR Wugang contributed RMB444,353,000 to the Group's revenue and RMB31,535,000 to the consolidated profit for the six months ended 30 June 2022.

Had the combination taken place at the beginning of the period, the revenue and consolidated profit for the six months ended 30 June 2022 of the Group would have been RMB2,917,217,000 and RMB206,477,000, respectively.

17. 業務合併(續)

華潤武鋼集團的業務合併產生商譽，是由於業務合併所支付的對價實際上包括(其中包括)結合華潤武鋼集團各自的營運預期產生協同效益所帶來的裨益的相關款額。該等裨益沒有與商譽分開確認，原因是該等裨益並未符合可識別無形資產的確認準則。所確認的商譽概不預期可用於扣減所得稅。

本次業務合併的現金流分析如下：

於業務合併日期，應收貿易款項及其他應收款項的公允價值分別為人民幣218,045,000元及人民幣31,127,000元。應收貿易款項及其他應收款項的總合同金額分別為人民幣267,495,000元及人民幣32,248,000元。

自業務合併以來，華潤武鋼在截至2022年6月30日止六個月內為本集團收益貢獻了人民幣444,353,000元，為綜合利潤貢獻了人民幣31,535,000元。

如果有關合併發生在期初，本集團期內的收益和綜合利潤將分別為人民幣2,917,217,000元和人民幣206,477,000元。

Notes to Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

30 June 2022 2022年6月30日

17. BUSINESS COMBINATION (continued)

Reconciliation of the carrying amount of the Group's goodwill at the beginning and end of the Reporting Period is presented below:

		RMB'000 人民幣千元 (Unaudited) (未經審核)
Gross carrying amount	總賬面值	
At 1 January 2022	於2022年1月1日	4,003,757
Deemed acquisition of subsidiaries	視為收購附屬公司	158,310
At 30 June 2022	於2022年6月30日	4,162,067
Accumulated impairment losses	累計減值虧損	
At 1 January 2022 and at 30 June 2022	於2022年1月1日及 2022年6月30日	(1,727,499)
Net carrying value	賬面淨值	
At 1 January 2022	於2022年1月1日	2,276,258
At 30 June 2022	於2022年6月30日	2,434,568

17. 業務合併(續)

本集團商譽賬面值於報告期初與報告期末的對賬呈列如下：

18. COMMITMENTS

The Group had the following capital commitments as at the end of the reporting periods:

18. 承擔

於報告期末，本集團有以下資本承擔：

		30 June 2022 2022年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2021 2021年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Contracted, but not provided for:	已訂約但未計提撥備：		
Property, plant and equipment	有關物業、廠房及設備	69,289	32,658

Notes to Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

30 June 2022 2022年6月30日

19. RELATED PARTY TRANSACTIONS

- (a) In addition to the balances, arrangements and transactions detailed elsewhere in this financial information, the Group had the following material transactions with related parties during the period:

19. 關聯方交易

- (a) 除本財務資料其他部分所載的結餘、安排和交易詳情外，本集團期內與關聯方的重大交易如下：

		For the six months ended 30 June 截至6月30日止六個月	
		2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元	2021 2021年 (Unaudited) (未經審核) RMB'000 人民幣千元
Healthcare services	醫療服務		
Subsidiaries controlled by China Resources Company Limited ("CR Co.")*	中國華潤有限公司 (「中國華潤」) 所控制的附屬公司*	648	448
Hospital management service	醫院管理服務		
An associate	一間聯營公司	9,409	13,194
Other hospital-derived services	其他醫院衍生服務		
Subsidiaries controlled by CR Co.	中國華潤所控制的附屬公司	89	357
Purchases of goods	採購貨品		
Subsidiaries controlled by CR Co.	中國華潤所控制的附屬公司	208,350	165,510
Investment income on financial assets at FVTPL	以公允價值計量且其變動計入損益的金融資產投資收入		
Subsidiaries controlled by CR Co.	中國華潤所控制的附屬公司	4,519	1
Interest income on bank deposits	銀行存款利息收入		
Subsidiaries controlled by CR Co.	中國華潤所控制的附屬公司	399	264
Other purchases and expenses	其他採購及費用		
Subsidiaries controlled by CR Co.	中國華潤所控制的附屬公司	1,566	1,254
Lease payments	租賃付款		
Subsidiaries controlled by CR Co.	中國華潤所控制的附屬公司	3,197	2,551

* CR Co. has significant influence over the Group.

* 中國華潤對本集團有重大影響力。

Notes to Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

30 June 2022 2022年6月30日

19. RELATED PARTY TRANSACTIONS

(continued)

(b) Outstanding balances with related parties

Due from related parties

		30 June 2022 2022年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2021 2021年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Trade in nature	貿易性質		
Subsidiaries controlled by CR Co.	中國華潤所控制的 附屬公司	2,664	5,294
An associate	一間聯營公司	3,236	—
		5,900	5,294
Non-trade in nature	非貿易性質		
Subsidiaries controlled by CR Co.	中國華潤所控制的 附屬公司	1,264	1,847
		7,164	7,141

An ageing analysis of the trade-related receivables as at the end of the reporting periods, based on the invoice date and net of loss allowance, is as follows:

於報告期末根據發票日期和扣除虧損撥備後的貿易相關應收款項的賬齡分析如下：

		30 June 2022 2022年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2021 2021年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Within 60 days	60天內	5,484	3,740
61 to 180 days	61天至180天	15	1,554
181 days to 1 year	181天至一年	401	—
		5,900	5,294

The amounts due from related parties are unsecured, interest-free and repayable within one year.

應收關聯方款項為無抵押、免息及須於一年內償還。

Notes to Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

30 June 2022 2022年6月30日

19. RELATED PARTY TRANSACTIONS

(continued)

(b) Outstanding balances with related parties (continued)

Due to related parties

		30 June 2022 2022年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2021 2021年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Subsidiaries controlled by CR Co.	中國華潤所控制的附屬公司		
Trade in nature	貿易性質	138,103	120,132
Non-trade in nature	非貿易性質	2,159	6,151
		140,262	126,283

The amounts due to related parties are unsecured, interest-free and repayable on demand.

Bank balances

		30 June 2022 2022年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2021 2021年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Subsidiaries controlled by CR Co.	中國華潤所控制的 附屬公司	150,997	93,280

The bank balances carried interest at a rate of 0.30% to 3.35% (31 December 2021: 0.30% to 4.20%) per annum.

19. 關聯方交易 (續)

(b) 與關聯方的尚未償還結餘 (續)

應付關聯方款項

銀行結餘

應付關聯方款項為無抵押、免息及須按要求償還。

銀行結餘乃按年利率0.30%至3.35% (2021年12月31日：0.30%至4.20%)計息。

19. RELATED PARTY TRANSACTIONS

(continued)

(c) Compensation of key management personnel of the Group

19. 關聯方交易 (續)

(c) 本集團主要管理人員之薪酬

		For the six months ended 30 June 截至6月30日止六個月	
		2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元	2021 2021年 (Unaudited) (未經審核) RMB'000 人民幣千元
Short term employee benefits	短期僱員福利	13,005	17,447
Post-employment benefits	離職後福利	205	188
Equity-settled shared-based payment expense	按權益結算以股份付款開支	709	1,525
Total compensation paid to key management personnel	向主要管理人員支付的薪酬總額	13,919	19,160

20. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

Management has assessed that the fair values of cash and cash equivalents, restricted and pledged bank deposits, trade and bills receivables, financial assets included in prepayments, deposits and other receivables, balances with related parties, the current portion of other financial assets at amortised cost, trade and bills payables, financial liabilities included in other payables and accruals, payables to the Sponsored Hospitals, interest-bearing bank borrowings and other borrowings approximate to their carrying amounts largely due to the short term maturities of these instruments.

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The following methods and assumptions were used to estimate the fair values:

The fair values of receivables from IOT hospitals and loan to a sponsored hospital have been calculated by discounting the expected future cash flows using rates currently available for instruments with similar terms, credit risk and remaining maturities.

The fair value of the listed financial assets at FVTPL is based on quoted market prices.

The fair values of the unlisted financial assets at FVTPL are estimated by using a discounted cash flow valuation model based on the market interest rates of instruments with similar terms and risks.

20. 金融工具的公允價值及公允價值層級

管理層評估了現金及現金等價物、限制性和已抵押銀行存款、應收貿易款項及應收票據、計入預付款項、保證金及其他應收款項的金融資產、與關聯方的結餘、其他按攤銷成本計量的金融資產的流動部分、應付貿易款項及應付票據、計入其他應付款項及應計費用的金融負債、應付舉辦權醫院款項以及計息銀行借款及其他借款，主要由於這些工具到期期限較短，所以其公允價值大致接近賬面值。

金融資產及負債的公允價值按當前交易（強制或清算出售除外）中雙方自願交換工具的金額入賬。以下方法和假設被用於評估公允價值：

來自IOT醫院之應收款項及向一間舉辦權醫院提供的貸款的公允價值乃按照其預期未來現金流量，採用具有類似條款、信貸風險及剩餘到期期限的工具現時可得利率貼現來計算。

以公允價值計量且其變動計入損益的上市金融資產的公允價值基於市場報價。

以公允價值計量且其變動計入損益的非上市金融資產的公允價值是根據具有類似條款和風險的工具的市場利率，採用貼現現金流量估值模型估算的。

20. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (continued)

Fair value hierarchy

The following tables illustrate the fair value measurement hierarchy of the Group's financial instruments:

Assets measured at fair value:

As at 30 June 2022

	Quoted prices in active markets (Level 1) 活躍市場之 報價 (第一級) (Unaudited) (未經審核) RMB'000 人民幣千元	Fair value measurement using 使用以下各項的公允價值計量		Total 總計 (Unaudited) (未經審核) RMB'000 人民幣千元	
		Significant observable inputs (Level 2) 重大可觀察 輸入值 (第二級) (Unaudited) (未經審核) RMB'000 人民幣千元	Significant unobservable inputs (Level 3) 重大不可觀察 輸入值 (第三級) (Unaudited) (未經審核) RMB'000 人民幣千元		
Financial assets at FVTPL	以公允價值計量且其 變動計入損益的 金融資產	58,882	80,674	—	139,556

As at 31 December 2021

	Quoted prices in active markets (Level 1) 活躍市場之 報價 (第一級) (Audited) (經審核) RMB'000 人民幣千元	Fair value measurement using 使用以下各項的公允價值計量		Total 總計 (Audited) (經審核) RMB'000 人民幣千元	
		Significant observable inputs (Level 2) 重大可觀察 輸入值 (第二級) (Audited) (經審核) RMB'000 人民幣千元	Significant unobservable inputs (Level 3) 重大不可觀察 輸入值 (第三級) (Audited) (經審核) RMB'000 人民幣千元		
Financial assets at FVTPL	以公允價值計量且其 變動計入損益的 金融資產	65,301	—	—	65,301

20. 金融工具的公允價值及公允價值層級(續)

公允價值層級

下表說明了本集團金融工具的公允價值計量層級：

按公允價值計量之資產：

於2022年6月30日

於2021年12月31日

Notes to Interim Condensed Consolidated Financial Information

中期簡明綜合財務資料附註

30 June 2022 2022年6月30日

20. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (continued)

The Group did not have any financial liabilities measured at fair value as at 30 June 2022 (31 December 2021: Nil).

During the period, there were no transfers of fair value measurements between Level 1 and Level 2 and no transfers into or out of Level 3 for both financial assets and financial liabilities (year ended 31 December 2021: Nil).

21. APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

The interim condensed consolidated financial information was approved and authorised for issue by the board of directors on 23 August 2022.

20. 金融工具的公允價值及公允價值層級(續)

截至2022年6月30日，本集團無任何以公允價值計量的金融負債(2021年12月31日：無)。

期內，金融資產及金融負債在第一級和第二級之間沒有公允價值計量的轉撥，也沒有轉入或轉出第三級(截至2021年12月31日止年度：無)。

21. 批准中期簡明綜合財務資料

中期簡明綜合財務資料已於2022年8月23日經董事會批准及授權刊發。

Definitions

釋義

“Audit Committee”	the audit committee of the Board
“Award Shares”	such Shares awarded pursuant to the Share Award Scheme, the maximum number of which shall not exceed 5% of the total issued capital of the Company as at August 31, 2018 and 1% of the total number issued Shares to each of the Selected Participants as at August 31, 2018
“Board” or “Board of Directors”	the board of Directors of our Company
“CG Code”	Corporate Governance Code as set out in Appendix 14 to the Listing Rules
“Chairman”	the chairman of our Board
“Chief Executive Officer”	the chief executive officer of the Company
“Chief Financial Officer”	the chief financial officer of the Company
“China” or “PRC”	the People’s Republic of China excluding, for the purpose of this report, Taiwan, the Macau Special Administrative Region and Hong Kong
“Company” or “our Company” or “China Resources Medical”	China Resources Medical Holdings Company Limited (華潤醫療控股有限公司), a company incorporated in the Cayman Islands with limited liability on February 28, 2013
“Controlling Shareholder(s)”	has the meaning ascribed thereto under the Listing Rules, or where the context requires, refers to China Resources Company Limited (中國華潤有限公司) (formerly known as China Resources National Corporation (中國華潤總公司))
“Corresponding Period”	the period from January 1, 2021 to June 30, 2021
“CR Healthcare”	China Resources Healthcare Group Limited, a company incorporated in Hong Kong with limited liability, and a subsidiary of CR Holdings
“CR Holdings”	China Resources (Holdings) Company Limited, a company incorporated in Hong Kong with limited liability, which is a wholly-owned subsidiary of China Resources Company Limited and the indirect holding company of CR Healthcare
“CR Hospital Management & Consulting”	China Resources Hospital Management & Consulting Co. Ltd. (formerly known as Beijing Phoenix United Hospital Management Consulting Co. Ltd., Beijing Phoenix United Hospital Management Co., Ltd. and Beijing Phoenix United Hospital Management Joint Stock Co., Ltd., a limited liability company established under the laws of the PRC on November 6, 2007, and a wholly-owned subsidiary of our Company

Definitions

釋義

「審核委員會」	指	董事會審核委員會
「獎勵股份」	指	根據股份獎勵計劃賞予的該等股份，其最高數目不得超過本公司於2018年8月31日已發行股本總數的5%及於2018年8月31日發行予各獲選參與者已發行股份總數的1%
「董事會」	指	本公司董事會
「企業管治守則」	指	上市規則附錄十四所載的企業管治守則
「董事長」	指	董事會董事長
「總裁」	指	本公司總裁
「首席財務官」	指	本公司首席財務官
「中國」	指	中華人民共和國；就本報告而言，不包括台灣、澳門特別行政區及香港
「本公司」或 「華潤醫療」	指	華潤醫療控股有限公司，一間於2013年2月28日在開曼群島註冊成立的有限責任公司
「控股股東」	指	具有上市規則所賦予該詞的涵義，視乎文義而定，指中國華潤有限公司（前稱中國華潤總公司）
「相應期間」	指	2021年1月1日至2021年6月30日期間
「華潤健康」	指	華潤健康集團有限公司，一間於香港註冊成立的有限公司，並為華潤集團之附屬公司
「華潤集團」	指	華潤(集團)有限公司，一間於香港註冊成立的有限公司，為中國華潤有限公司的全資附屬公司及華潤健康的間接控股公司
「華潤醫院管理諮詢」	指	華潤醫院管理諮詢有限公司(前稱北京鳳凰聯合醫院管理諮詢有限公司、北京鳳凰聯合醫院管理有限公司及北京鳳凰聯合醫院管理股份有限公司)，一間於2007年11月6日根據中國法律成立的有限責任公司，為本公司全資附屬公司

“CR Wugang”	China Resources Wugang (Hubei) Hospital Management Co., Ltd., a company incorporated in China with limited liability, which is 51% held by the Group and 49% held by Wuhan Iron and Steel (Group) Corporation
“Director(s)”	the directors of our Company or any of them
“Eligible Persons”	any of the (i) key management personnel including the Directors and senior management of the Group; (ii) employed experts as nominated by the Board; and (iii) core employees of the Group
“Group”, “our Group”, “we” or “us”	our Company and its subsidiaries
“HK\$” or “HKD” and “HK cent(s)” or “cent(s)”	Hong Kong dollar and cent(s) respectively, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Huaikuang Hospital”	Huaibei Miner General Hospital* (淮北礦工總醫院)
“Huaikuang Hospital Group”	collectively, Huaikuang Hospital and certain affiliated hospitals and community clinics
“Huaiyin Hospital”	Huai’an City Huaiyin Hospital Company Limited, a company established in the PRC with limited liability
“Hubei Runkang”	Hubei Runkang Healthcare Management Company Limited, a company incorporated in the PRC with limited liability and a subsidiary of the Company
“IOT”	the “invest-operate-transfer” model
“IOT Hospitals”	third-party hospitals and clinics, which we manage and operate under the IOT model
“Jian Gong Hospital”	Beijing Jian Gong Hospital Co., Ltd.* (北京市健宮醫院有限公司), a limited liability company established under the laws of the PRC on May 12, 2003 and a subsidiary of our Company, and its predecessor, Beijing Construction Worker Hospital (北京市建築工人醫院), before its reform
“Jinan Zhong Qi Hospital”	Jinan Zhong Qi Hospital Company Limited* (濟南重汽醫院有限公司, a limited liability company established under the laws of the PRC), a wholly-owned subsidiary of our Company, and its predecessor, CNHTC Hospital (中國重型汽車集團有限公司醫院), before its reform
“Jing Mei Group”	Beijing Jing Mei Group Company Limited, a company incorporated in the PRC with limited liability and a state-owned enterprise under the State-owned Assets Supervision and Administration Commission of Beijing

Definitions

釋義

「華潤武鋼合營公司」	指	華潤武鋼(湖北)醫院管理有限公司，一間於中國註冊成立的有限公司，而彼由本集團及武漢鋼鐵(集團)公司分別持有51%及49%股權
「董事」	指	本公司全體董事或任何一位董事
「合資格人士」	指	任何(i)主要管理人員，包括本集團的董事及高級管理層；(ii)由董事會提名的受聘專家；及(iii)本集團的核心僱員
「本集團」	指	本公司及其附屬公司
「港元」和「港仙」	指	分別為港元及仙，香港法定貨幣
「香港」	指	中國香港特別行政區
「淮礦醫院」	指	淮北礦工總醫院
「淮礦醫院集團」	指	淮礦醫院及其附屬的多家及社區診所的統稱
「淮陰醫院」	指	淮安市淮陰醫院有限公司，一間於中國成立的有限公司
「湖北潤康」	指	湖北潤康醫療管理有限責任公司，一家於中國註冊成立的有限公司，並為本公司之附屬公司
「IOT」	指	「投資 — 營運 — 移交」模式
「IOT醫院」	指	本集團採用IOT模式管理和營運的第三方醫院及診所
「健宮醫院」	指	北京市健宮醫院有限公司(改組前為北京市建築工人醫院)，一間於2003年5月12日根據中國法律註冊成立的有限責任公司，為本公司之附屬公司
「濟南重汽醫院」	指	濟南重汽醫院有限公司(改組前為中國重型汽車集團有限公司醫院)，一間根據中國法律註冊成立的有限責任公司，為本公司之全資附屬公司
「京煤集團」	指	北京京煤集團有限責任公司，一家於中國成立之有限公司，是北京市國資委下屬之國有獨資企業

“Jing Mei Hospital”	Jing Mei Hospital* (北京京煤集團總醫院)
“Jing Mei Hospital Group”	collectively, Jing Mei Hospital and its affiliated grade I hospitals and community clinics
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“Mentougou Hospital”	Beijing Mentougou Hospital (北京市門頭溝區醫院), a not-for-profit hospital established under the laws of the PRC in 1951 and wholly-owned by the Mentougou District government, which we began managing in June 2010 pursuant to the Mentougou IOT Agreement
“Mentougou Hospital for Women and Children”	Mentougou Hospital for Women and Children (門頭溝區婦幼保健院) incorporated under the laws of the PRC in 1983 and wholly-owned by the Mentougou District government, which we began managing in September 2014 pursuant to the Mentougou Hospital for Women and Children IOT Agreement
“Mentougou Hospital for Women and Children IOT Agreement”	the IOT agreement we entered into with the Mentougou District government on September 23, 2014
“Mentougou IOT Agreement”	collectively, the IOT agreement we entered into with the Mentougou District government on July 30, 2010, as amended
“Mentougou TCM Hospital IOT Agreement”	the IOT agreement we entered into with the Mentougou District government on June 6, 2012
“Mentougou Traditional Chinese Medicine Hospital”	Mentougou Traditional Chinese Medicine Hospital (北京市門頭溝區中醫院), a not-for-profit hospital established under the laws of the PRC in 1956 and wholly-owned by the Mentougou District government, which we began managing in June 2012 pursuant to the Mentougou TCM Hospital IOT Agreement
“Model Code”	The Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix 10 to the Listing Rules
“Nomination Committee”	the nomination committee of the Board
“OT”	the “operate-transfer” model
“OT Hospital”	third-party hospitals which we manage and operate under the OT model
“Remuneration Committee”	the remuneration committee of the Board
“Reporting Period”	six months ended June 30, 2022

Definitions

釋義

「京煤醫院」	指	北京京煤集團總醫院
「京煤醫院集團」	指	京煤醫院及其附屬的一級醫院和社區診所的統稱
「上市規則」	指	聯交所證券上市規則
「門頭溝區醫院」	指	北京市門頭溝區醫院，一家由門頭溝區政府全資擁有的非營利醫院，於1951年根據中國法律成立，本集團根據門頭溝IOT協議於2010年6月開始對其進行管理
「門頭溝區婦幼保健院」	指	門頭溝區婦幼保健院，於1983年根據中國法律註冊成立，由門頭溝區政府全資擁有，本集團根據門頭溝區婦幼保健院IOT協議於2014年9月開始對其進行管理
「門頭溝區婦幼保健院IOT協議」	指	本集團與門頭溝區政府於2014年9月23日訂立之IOT協議
「門頭溝IOT協議」	指	本集團與門頭溝區政府於2010年7月30日訂立的IOT協議（經修訂）的統稱
「門頭溝區中醫院IOT協議」	指	本集團與門頭溝區政府於2012年6月6日訂立的IOT協議
「門頭溝區中醫院」	指	北京市門頭溝區中醫院，一家由門頭溝區政府全資擁有的非營利醫院，於1956年根據中國法律成立，本集團根據門頭溝區中醫院IOT協議於2012年6月開始對其進行管理
「標準守則」	指	上市規則附錄10所載上市發行人董事進行證券交易的標準守則
「提名委員會」	指	董事會提名委員會
「OT」	指	「營運 — 移交」模式
「OT醫院」	指	本集團採用OT模式管理和營運的第三方醫院
「薪酬委員會」	指	董事會薪酬委員會
「報告期」	指	截至2022年6月30日止六個月

“RMB”	Renminbi, the lawful currency of the PRC
“Run Neng Hospitals”	collectively, Guangdong CEEC Power Hospital* (廣東中能建電力醫院), Beijing CEEC Hospital* (北京中能建醫院), Beijing CEEC Hospital Shuozhou Hospital* (北京中能建朔州醫院), Guangxi Hydropower Hospital* (廣西水電醫院) and Hefei Gaoxin District Changning Community Healthcare Center* (合肥高新區長寧社區衛生服務中心), Tiandong Street Dianchang Road Community Healthcare Center* (田東街道電廠路社區衛生服務中心), Gaoxin District Tianle Community Healthcare Center* (高新區天樂社區衛生服務中心) and Gaoxin District Xingyuan Community Healthcare Center* (高新區興園社區衛生服務中心)
“Selected Participant(s)”	Eligible Persons selected by the Board in accordance with the terms of the Share Award Scheme
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
“Share(s)”	share(s) with par value of HK\$0.00025 each in the capital of our Company
“Shareholder(s)”	holder(s) of the Share(s)
“Share Award Scheme”	the share award scheme of the Company adopted by the Board pursuant to a resolution passed by the Board on July 7, 2014, as amended by the Board on May 25, 2015 and August 31, 2018
“Share Option Scheme”	the share option scheme conditionally adopted by the Company pursuant to a resolution passed by our Shareholders on September 30, 2013
“Stock Exchange”	the Stock Exchange of Hong Kong Limited
“UMP Healthcare Holdings”	UMP Healthcare Holdings Limited (聯合醫務集團有限公司), a limited liability company incorporated in the Cayman Islands, whose shares are listed on the Stock Exchange (stock code: 722)
“Unison Champ”	Unison Champ Premium Limited (formerly known as Unison Champ Limited), a company incorporated under the laws of British Virgin Islands and a wholly-owned subsidiary of the Company
“U.S. dollar” or “US\$”	United States dollar, the lawful currency of the United States of America
“Wugang Hospital”	China Resources Wugang General Hospital* (華潤武鋼總醫院)
“Wugang Hospital Group”	collectively, Wugang Hospital, Wuhan Iron and Steel (Group) Corporation No. 2 Staff Hospital* (武漢鋼鐵(集團)公司第二職工醫院) and certain affiliated hospitals and community clinics

Definitions

釋義

「人民幣」	指	人民幣，中國法定貨幣
「潤能系醫院」	指	廣東中能建電力醫院、北京中能建醫院、北京中能建朔州醫院、廣西水電醫院及合肥高新區長寧社區衛生服務中心、田東街道電廠路社區衛生服務中心、高新區天樂社區衛生服務中心、高新區興園社區衛生服務中心之統稱
「獲選參與者」	指	董事會根據股份獎勵計劃條款挑選的合資格人士
「證券及期貨條例」	指	香港法例第571章證券及期貨條例(經不時修訂、補充或以其他方式修改)
「股份」	指	本公司股本中每股面值0.00025港元的股份
「股東」	指	股份持有人
「股份獎勵計劃」	指	董事會根據董事會於2014年7月7日通過的一項決議案所採納的本公司股份獎勵計劃，經董事會於2015年5月25日及2018年8月31日修訂
「購股權計劃」	指	本公司依據於2013年9月30日通過的股東決議案有條件採納的購股權計劃
「聯交所」	指	香港聯合交易所有限公司
「聯合醫務集團」	指	聯合醫務集團有限公司，一間在開曼群島註冊成立的有限責任公司，其股份於聯交所上市(股份代號：722)
「和凱」	指	和凱第一有限公司(前稱和凱有限公司)，一間根據英屬維爾京群島法律註冊成立的公司，並為本公司之全資附屬公司
「美元」	指	美元，美利堅合眾國法定貨幣
「武鋼醫院」	指	華潤武鋼總醫院
「武鋼醫院集團」	指	武鋼醫院、武漢鋼鐵(集團)公司第二職工醫院及其附屬的多家醫院及社區診所的統稱

“Xukuang Hospital”	Xuzhou Mining Hospital* (徐州市礦山醫院)
“Yan Hua Hospital”	Yan Hua Hospital* (北京燕化醫院)
“Yan Hua Hospital Group”	collectively, Yan Hua Hospital and the community clinics affiliated with Yan Hua Hospital
“Yan Hua Hospital Investment Management Agreement”	the hospital investment management agreement dated February 4, 2008, which was supplemented in April 2008, December 2010, June 2011, July 2013, September 2013 and October 2013, and were entered into between CR Hospital Management & Consulting, Yan Hua Hospital and Yan Hua Phoenix
“Yan Hua IOT Agreement”	the hospital management right and investment framework agreement dated February 1, 2008 and the Yan Hua Hospital Investment Management Agreement dated February 4, 2008, both of which were supplemented in April 2008, December 2010, June 2011, June 2013, July 2013, September 2013 and October 2013, entered into by CR Hospital Management & Consulting with Yan Hua Phoenix and Yan Hua Hospital Group
“Yan Hua Phoenix”	Beijing Yan Hua Phoenix Healthcare Asset Management Co., Ltd.* (北京燕化鳳凰醫療資產管理有限公司), a limited liability company incorporated under the laws of the PRC on July 18, 2005
“Yuenianhua Rehabilitation Hospital”	Nanning Yuenianhua Rehabilitation Hospital Co. Ltd.* (南寧市悦年華康復醫院有限公司), a limited company established under the laws of the PRC and a for profit hospital focusing on rehabilitation specially

* Denotes English translation of the name of a Chinese entity is provided for identification purpose only.

In this report, the terms “associate”, “connected person”, “connected transaction”, “subsidiary” and “substantial shareholder” shall have the same meanings ascribed thereto under in the Listing Rules, unless the context otherwise requires.

Definitions

釋義

「徐礦醫院」	指	徐州市礦山醫院
「燕化醫院」	指	北京燕化醫院
「燕化醫院集團」	指	燕化醫院及其附屬之社區診所的統稱
「燕化醫院投資管理協議」	指	由華潤醫院管理諮詢、燕化醫院以及燕化鳳凰簽訂的日期為2008年2月4日的醫院投資管理協議，於2008年4月、2010年12月、2011年6月、2013年7月、2013年9月及2013年10月經補充
「燕化IOT協議」	指	由華潤醫院管理諮詢、燕化醫院集團以及燕化鳳凰簽訂的日期為2008年2月1日的醫院管理權利與投資框架協議，及日期為2008年2月4日的燕化醫院投資管理協議的統稱，兩都均於2008年4月、2010年12月、2011年6月、2013年6月、2013年7月、2013年9月及2013年10月經補充
「燕化鳳凰」	指	北京燕化鳳凰醫療資產管理有限公司，一間於2005年7月18日根據中國法律註冊成立的有限責任公司
「悦年華康復醫院」	指	南寧悦年華康復醫院有限公司，一間根據中國法律註冊成立的有限責任公司，以及為一間以復康專科為主的營利性醫院

在本報告中，除文義另有所指外，「聯繫人」、「關連人士」、「關連交易」、「附屬公司」及「主要股東」應具有上市規則所賦予該等詞彙的相同涵義。



華潤醫療控股有限公司

China Resources Medical Holdings Company Limited



This interim report is printed on environmental paper
此中期報告以環保紙張印製